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LIST OF ABBREVIATIONS 
 
• bovine albumin serine (BSA) • integrated peak mass area (PA) 
• Darbepoetin alfa (DPO or Darbe) • intramuscular (IM) 
• electrospray ionization in positive 
mode (ESI+) 
• intravenous (IV) 
 
• endogenous equine EPO (eEPO) • micron (µ) 
• Epoetin alfa (rhEPO) • minute (min) 
• extracted ion chromatogram (EIC) • parts per billion (ppb) 
• Iowa State University (ISU) • parts per million (ppm) 
• liquid chromatography mass 
spectrometer (LC-MS) 
• retention time (RT) 
• limit of detection (LOD) • tandem mass spectrometry (MS/MS) 
• The Guan et al. 2008 substituted with the (ISU) developed HPLC gradient and the 7 
and 5 minutes for the first and second optimal incubation times, respectively, with 
49.4 µg trypsin per mL of sample digest or 4 µg trypsin method abbreviated as the 
resulting (ISU) method or resulting (ISU) method modified from the Guan et al. 2007 
and 2008 methods. 
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ABSTRACT 
 
Recombinant human erythropoietin (rhEPO) and Darbepoetin alfa (Darbe) are 
erythropoietic drugs that must be monitored for possible abuse in horse racing sporting 
events. An improved detecton method modified from literature methods was developed for 
confirmative and semi-quantitative analysis of these erythropoietic drugs in equine plasma 
samples. Anti-rhEPO antibodies coated onto magnetic beads were used for immunoaffinity 
separation to extract any rhEPO and/or Darbe present in equine plasma samples. The rhEPO 
and/or Darbe bound onto the antibody coated magnetic beads were extracted with a 0.1% 
polyethylene glycol (PEG) pH 2.0 buffer solution. A buffer exchange procedure was 
performed to eliminate PEG and to concentrate the proteins. The extracted rhEPO and/or 
Darbe were incubated at 80 oC for 10 minutes to denature the proteins. This work found that 
7 minutes incubation at 80 oC was the optimal of the incubation times tested for Darbe and 
rhEPO proteins denaturation.  
Subsequently, trypsin was added into the denatured protein sample to digest the 
extracted Darbe and/or rhEPO into peptide fragments generating T9 peptide from Darbe 
which was specific and unique to Darbe and the T5 peptide from rhEPO which was specific 
and unique to rhEPO. The trypsin digestion also generated T17 and T6 peptides from rhEPO 
and Darbe which were specific and unique to both rhEPO and Darbe. This work found that 
doubling the trypsin concentration in trypsin digestion method from 2 µg (24.7 µg per mL of 
digest) to 4 µg (49.4 µg per mL of digest) increased the detection of T17, T6, and T9 peptides 
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from 1177, 821, 7385 integrated peak mass areas for T17, T6, and T9 peptides, respectively, 
to 2653, 857, and 7518 integrated peak mass areas for T17, T6, and T9 peptides, respectively. 
The trypsin digested sample was incubated for 10 minutes at 80 oC to deactivate 
trypsin in the sample digest. This work found that 5 minutes incubation at 80 oC was the 
optimal of the incubation times tested for trypsin deactivation. PNGase F [Peptide-N4-
(acetyl-ß-glucosaminyl)- asparagine amidase] enzyme was added to deglycosylate the tryptic 
peptide fragments. This work confirmed the work of Guan et al. (2008) that deglycosylation 
of T9 and T5 peptides of Darbe and rhEPO, respectively, were necessary for detection in 
electropray ionization in positive ion mode liquid chromatography mass spectrometry (ESI+ / 
LC-MS) of the glycosylated TT9 and T5 peptides because the glycosylation sites of the T9 
and T5 peptides suppressed ionization resulting in no detecting of the compounds. This work 
found that the detection of T17 and T6 peptides also improved from 581 and 811 integrated 
peak mass areas for T17 and T6 peptides, respectively, to 1004 and 861 integrated peak mass 
areas for T17 and T6 peptides, respectively, after treated the tryptic digest with PNGase F. 
Subsequently, the sample digest was detected using ESI+ / LC-MS by monitoring the 
molecular ions of T17, T6, T9, and T5 peptides and further confirmed by the retention times 
and the product ions match up with the ones generated by the peptides of the standard digest.  
Darbe spiked in equine plasma from 0.05 to 2.5 ng/mL (parts per billion or ppb) and 
the rhEPO drug spiked in equine plasma from 0.1 to 2.5 ppb were extracted and identified by 
the resulting (ISU) method modified from the Guan et al. (2007 and 2008) methods. Plasma 
samples from a research horse before and after administration by intramuscular injection at 
0.4 µg/kg of Darbe and from another research horse before and after administration by 
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intravenous injection at 0.3 µg/kg of rhEPO were collected and analyzed by the resulting 
(ISU) method. The pre-injection plasma sample from both horses did not detect the presence 
of Darbe and rhEPO compounds. The Darbe compounds were detected for all the post-
injection plasma samples from the horse administered with Darbe from 2 to 192 hours 
samples. The four hours post-injection plasma sample from the horse administered with 
rhEPO was detected for the presence of the rhEPO compounds. In summary, the resulting 
(ISU) method developed from the modifications of the Guan et al. (2007 and 2008) methods 
were capable of extracting, detecting, and confirming the presence of Darbe and/or rhEPO in 
spiked and administration equine plasma samples. 
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CHAPTER 1: INTRODUCTION 
 
Darbepoetin alfa (Darbe) and recombinant human erythropoietin (rhEPO) protein 
drugs stimulate erythropoiesis increasing red blood cell mass in the body; therefore, 
increasing the oxygen carrying capacity to working muscles and enhance performance. A 
reliable method to detect and confirm the presence of these erythropoietic drugs needs to be 
developed to monitor the possible abuse of rhEPO and Darbe drugs in horse racing sporting 
events. Protein drugs have posed a significant problem to traditional drug testing techniques 
that targeted small molecular weight drugs. Recently, electrospray ionization liquid 
chromatography mass spectrometry (ESI-LC-MS) has been employed to detect rhEPO and 
Darbe in equine blood samples, utilizing a combination of immunoaffinity separation to 
extract the proteins, enzymes to digest the proteins into peptides, and ESI-LC-MS to detect 
and confirm the peptides, which are specific and unique to the protein drug of interest. This 
technique provides a mass spectral data of the suspicious protein drug that can be used to 
challenge in court hearings. 
The works by Guan et al. 2007 and 2008 applied this principle that allowed them to 
confirm and differentiate rhEPO and Darbe in equine blood samples. Darbe and rhEPO 
proteins were extracted from plasma by immunoaffinity purification with antibodies against 
rhEPO (Guan et al. 2007 and 2008). Trypsin, a serine protease that specifically cleaves 
arginine and lysine at their carboxylic sides, was used to digest the glycoproteins to generate 
peptide fragments that are unique only to rhEPO and Darbe (Guan et al., 2007 and 2008). The 
tryptic digest sample was treated with PNGase F [Peptide-N4-(acetyl-ß-glucosaminyl)- 
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asparagine amidase] enzyme to deglycosylate the peptides (Guan et al., 2008). The tryptic 
peptide fragments sixth [46VNFYAWK52 (T6) with mass-to-charge (m/z) 464.5] and 
seventeenth [144VYSNFLR150 (T17) with m/z 450.0] of Darbe and rhEPO amino acid 
sequences were specific and unique to Darbe and rhEPO (Guan et al., 2007). They were used 
to confirm Darbe and/or rhEPO from other compounds in equine plasma samples. 
Additionally, two deglycosylated tryptic peptides, the ninth peptide fragment 
[77GQALLVNSSQVNETLQLHVDK97 (T9) with m/z 766.4] from Darbe amino acid 
sequence and the fifth peptide fragment [21EAENITTGCAEHCSLNENITVPDTK45 (T5) 
with m/z 897.8] from rhEPO amino acid sequence, were used to differentiation between 
Darbe and rhEPO, and from other compounds in equine blood samples (Guan et al., 2008). 
The T17, T6, T9, and T5 peptides were identified by ESI-LC-MS. 
The current research adopted the Guan et al. 2007 and 2008 Darbe and rhEPO testing 
methods and developed an HPLC method allowing chromatographic separation and 
sequential detection of all four peptides (T17, T6, T9, and T5) in the same analysis. The 
current work evaluated whether the increase in trypsin concentration of the sample digestion 
method would have an effect in the recovery of the peptides. The current work evaluated 
whether protein samples digested with PNGase F as compared to untreated protein samples 
would have an effect in the sensitivity in the detection of peptides by electropspray positive 
ion mode LC-MS. The resulting (ISU) method modified from the Guan et al. 2007 and 2008 
methods was applied to identify and confirm Darbe and rhEPO in Darbe spiked plasma and 
rhEPO spiked plasma samples. The resulting (ISU) method was also used to identify and 
confirm Darbe and rhEPO in blood samples collected from a horse administered with Darbe 
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by intramuscular injection and from another horse administered with rhEPO by intravenous 
injection. 
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CHAPTER 2: LITERATURE REVIEW 
 
ERYTHROPOIETIN  
 
Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney that 
stimulates erythropoiesis (Jelkmann, 2004). Human EPO is 165 amino acids long and has a 
molecular mass of 30.4 kDa and migrates with an apparent size of 34-38 kDa on SDS-
polyacrylamide gels (Davis et al., 1987).  Approximately 40% of the molecule is 
carbohydrate that consists of 3 N-linked glycans at Asn 24, 38, and 83, and one O-linked 
glycan at Ser 126 (Nimtz et al., 1993). The glycosylation of the molecule can be different 
between EPO isoforms (proteins with the same functions but have similar and not identical 
structures) and can affect the biological activity, metabolic fate, stability and solubility of the 
glycoproteins (Kawasaki, 2000). The N-glycans have terminal sialic acid residues (Nimtz et 
al., 1993) that are essential to the biological activity of EPO in vivo (Jelkmann, 2007). The 
addition of extra N-glycans with sialic acid onto EPO can increase biological activity and 
stability of the glycoprotein in vivo (Stubiger et al., 2005a; Elliot et al., 2003). 
The free ligand form of EPO structure is an elongated molecule of 47 Å x 35 Å x 25 
Å of a left-handed four-helix bundle (Figure 1). This bundle (denoted as A, B, C, and D in 
Figure 1) is a four long α-helices running in an up-up-down-down direction and connected by 
a short and two long crossover loops (Figure 1). A short stretch of antiparallel β-sheets 
formed within the two long cross-over loops (Figure 1). The faces of the free ligand EPO 
structure away from the two long crossover loops are amino acid residues that are involved in 
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receptor binding (Figure 1). These residues are clustered into two patches on the EPO surface 
(Cheetham et al., 1998). The first patch is considered as the high-affinity receptor binding site 
that plays a structural rather than functional role in receptor binding (Cheetham et al., 1998). 
The second patch or binding site 2 is the low affinity receptor binding site that lies within the 
helical-bundle face (Cheetham et al., 1998). The EPO receptor (EPOR) is a dimeric molecule 
(Syed et al., 1998). The ligand-receptor complex of EPO has a unique orientation and a 120o 
angular relationship that is crucial to the activation of the signaling cascade (Syed et al., 
1998). Once EPO is bound to the EPOR, the EPO structure will change slightly (Cheetham et 
al., 1998) and a disulphide bond will form between the dimer molecules of the receptor 
resulting in the initiation of the signaling cascade (Syed et al., 1998).  
 
 
 
 
 
 
 
 
 
 6 
NMR structure of human erythropoietin and a comparison with its receptor bound 
conformation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cheetham et al. (1998), Nature Structural Biology, 5 : 861-866. 
 
Copyright ©1998       Nature Publishing Group 
 
Figure 1. The free ligand form of erythropoietin structure. The four red cylinders denoted as A, B, C, and D 
are the α-helices. The S1 and S2 are the two β-strands in the crossover loops. The B’ is the β-helix. The 
remainder of the structure that colored blue is the Cα chain trace with the C- and N-termini. This figure was 
copied from Cheetham et al. (1998) with permissions from the Nature Publishing Group (75 Varick Street, 9th 
Floor, New York,  NY 10013, USA, permissions@nature.org).  
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Recombinant human EPO 
Recombinant human EPO (rhEPO) is used for the treatment of clinical anemia by 
stimulating the production of red blood cells (RBCs). A second generation rhEPO, 
darbepoetin alfa (Darbe), is a hyperglycosylated rhEPO that is synthesized from Chinese 
hamster ovary cells. Due to Darbe’s increased glycosylation content, it has a larger negative 
charge, a higher molecular weight, and a three times longer circulating half-life than rhEPO 
(Egrie et al., 2001 & 2003). The potency in vivo of Darbe is almost 4 times greater than 
rhEPO when they were administered 3 times a week and almost 14 times greater than rhEPO 
when they were administered once a week (Egrie et al., 2001 & 2003). The mean half-life of 
rhEPO and Darbe in human by intravenous injection was 8.5 hours and 25.3 hours, 
respectively (MacDougall et al., 1999). The average half-life of Darbe by subcutaneous 
injection was 48.8 hours (MacDougall et al., 1999). Darbe and rhEPO stimulate 
erythropoiesis resulting in elevation of hematocrit and subsequent increase oxygen-carrying 
capacity of blood (Ekblom et al., 1972). Therefore, humans and equines athletes dosed with 
Darbe or rhEPO will increase their aerobic capacity and can potentially improve performance 
(Kearns et al., 2000). 
There are different types of recombinant human erythropoietins (epoetins). Currently, 
the three commercially available epoetins are epoetin-α (Procrit® and Epogen® from Amgen 
Corp., Thousand Oaks, CA; and Eprex® from Ortho Biologics of Johnson and Johnson 
subsidiary, Puerto Rico), epoetin-β (CERA® from France Biotech Inc., Paris, France; 
Neorecormon® and Recormon® from Roche Corp., Nutley, NJ), and epoetin-ω (EPOmax® 
from Elanex Pharmaceuticals, Inc., Bothell, WA). Also, the gene-activated EPO, epoetin-δ  
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(Dynepo®, from Shire Pharmaceuticals Corp., Wayne, PA), synthesized from human 
fibrosarcoma cells has recently been approved by the European Union (Jelkmann, W., 2007). 
Although, these epoetins compose of the same amino acid sequences, they are different from 
each other by size, charge, and carbohydrate heterogeneity. 
The use of EPO in sports has been prohibited by the International Olympic 
Committee (IOC) and the World Anti-Doping Agency (WADA) since 1990 (Thevis & 
Schanzer, 2007) due to ethical and health reasons. The abusive uses of pharmaceutical EPO 
can lead to health risks and in a severe case even death from clotting, stroke, or heart attacks 
(Robinson et al., 2003; Catlin and Murray, 1996). Therefore, it is important to have a reliable 
and sensitive anti-doping EPO method to combat cheating in order to ensure fairness in 
competition, safety, and health of equine athletes. 
Figure 2 showed the amino acid sequence, glycosylation sites, and trypsin cleavage 
sites of recombinant human erythropoietin. The sequence of Darbe is similar to rhEPO except 
for 5 amino acids at the following positions: Alanine abbreviated as “A” at position 30 is 
replaced by asparagine abbreviated as “N”; histidine abbreviated as “H” at position 32 is 
replaced by threonine “T”; proline abbreviated as “P” at position 87 is replaced by valine 
“V”;  tryptophan abbreviated as “W” at position 88 is replaced by asparagine; and proline at 
position 90 is replaced by threonine (Figure 2). Trypsin is a serine protease that cleaves at 
arginine (R) and lysine (K) at the carboxylic sides generating peptide sequences. The T17 and 
T6 peptides generated by trypsin cleavage of rhEPO and Darbe were used for confirmation of 
rhEPO and Darbe in equine blood samples. The T9 peptide generated by trypsin cleavage of 
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Darbe is specific and unique to Darbe.  The T5 peptide generated by trypsin cleavage of 
rhEPO is specific and unique to rhEPO. 
 
A.A. 
# Amino Acid (A.A.) Sequence of rhEPO 
1 APPR↓LICDSR↓ VLERYLLEAK↓ 21EAENITTGC A EHCSLNENIT40VPDTK↓45(T5) 
46 46VNFYA WK↓52(T6)  R↓MEVGQQA VEVWQGLALL SEAVL R↓  
77 77GQALLVNSSQ P WEP LQLHVDK↓97(T9) AVSGLR↓SLTTLLR↓ ALGAQK↓EAIS 
121 PPDAASAAPL R↓TITADTFR↓K↓ LFR↓ 144VYSNFLR↓150(T17) GK↓LK↓LYTGEA 
161 CRTGD 
Alanine (A), arginine (R), Asparagine (N), aspartic acid (D), cysteine (C), glutamic acid (E), 
glutamine (Q), glycine (G), histidine (H), isoleucine (I), leucine (L), lysine (K), methionine (M), 
phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y), valine (V). 
Figure 2. The amino acid sequence, glycosylation sites, and trypsin cleavage sites of recombinant human 
erythropoietin (rhEPO). The glycosylation sites, which colored blue, are 24N, 38N, 83N, and 126S. The arrows 
(↓) designated the cleavage sites by trypsin that cleaves at arginine (R) and lysine (K) at their carboxylic sides. 
The T17, T6, T9, and T5 peptides are colored red. The bottom of graph listed the abbreviations for the amino 
acids (A.A.). 
 
 
Specimen and challenge in EPO testing 
The detection of rhEPO and Darbe from endogenous equine EPO (eEPO) are difficult 
when compare to other protein hormones because their amino acid sequences and masses are 
similar (Lasne et al., 2001 & 2003; Trout et al., 2003). Also, the EPO isoforms are usually 
present in very low concentrations in both blood and urine samples. Blood samples are more 
suitable to be used in protein drug testing analysis because the levels of parent protein drugs 
and metabolites in blood compared to urine are much higher (Rivier, 2000). The plasma 
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portion was separated from blood and was used in detection of protein drugs. Plasma is the 
liquid component of blood and usually makes up approximately 55% of the total blood 
volume. Plasma contains proteins, electrolytes, and water. The plasma portion of blood from 
an animal doped with novel erythropoiesis stimulating agents would to be higher than 
normal. Serum is blood plasma without protein clotting factors. Protein drugs are less stable 
than small molecular weight molecules. Also, the EPO drugs introduced are similar in the 
amino acid sequences and the physiochemical properties to the naturally occurring protein 
hormone produced by the animal.  
 
Immunoassay testing of EPO drugs 
Immunoassays techniques have been traditionally used to screen samples for the 
presence of drugs. Immunoassays such as enzyme-linked immunosorbent assay (ELISA) and 
radioimmunoassay (RIA) are being used today to screen EPO drug samples because the tests 
are inexpensive, sensitive, rapid, and require only a small amount of sample.  
The problem of using immunoassay to confirm rhEPO in equine plasma is that there 
maybe cross-reactivity between recombinant human and equine erythropoietins. The 
erythropoietin (EPO) gene is highly conserved among mammals, which allows antibodies 
made for human EPO to be used to detect equine EPO (Kearns et al., 2000). In fact, human 
EPO is approximately 80% homologous to horse EPO in both cDNA and amino acid 
sequence (Wen et al., 1993). A study by Kearns and associates using western blot analysis 
demonstrated that there was cross-reactivity between polyclonal anti-human erythropoietin 
antibody and horse erythropoietins indicating that human EPO antibody recognized equine 
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EPO as well as rhEPO. This causes a major problem for detection of rhEPO by 
immunoassays in equine blood samples. Immunoassay tests are also susceptible to non-
specific reactivity with other substances or proteins in the samples (Hilderbrand et al., 2003). 
Newer immunoassay kits use monoclonal antibodies that theoretically have higher specificity 
than polyclonal antibody kits (Hilderbrand et al., 2003). However, cross-reactivity still occurs 
within sample or with other proteins producing suspicious results (Hilderbrand et al., 2003). 
A more sophisticated method was needed that would allow scientists to detect and 
discriminate between rhEPO, Darbe, and endogenous equine EPO. 
 
IEF, SDS-PAGE, and 2 Dimensional Gel EPO drugs analyses 
A test method that claimed to be successfully detect and discriminate rhEPO and 
Darbe for endogenous EPO was isoelectric focusing (IEF). IEF had been used to successfully 
separate different types of EPO isoforms in a pH gradient (Catlin et al., 2002; Lasne & De 
Ceaurriz, 2000; Lasne et al., 2001). Figure 3 was copied from Catlin et al. (2002) showed that 
the EPO isoforms were separated and identified by IEF. The rhEPO standards (lanes 1 and 4 
of Figure 1), endogenous human EPO (lane 2 of Figure 1), Darbe standard (lanes 5 and 7 of 
Figure 1), rhEPO extract from person administered with rhEPO (lane 3 of Figure 1), and 
Darbe extract from person administered with Darbe (lane 6 of Figure 1) showed their own 
unique migration patterns that are different from each other. 
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Figure 3. The cathode and anode sides of Figure 1 are indicated as negative and positive, respectively (Catlin et 
al., 2002). Lanes 1 and 4 are the rhEPO standards; lane 2 is the endogenous human EPO extracted from the 
urine of a healthy person; lane 3 was a urine extract of rhEPO from a person administered with rhEPO; lane 6 
was a urine extract of Darbe from a person administered with Darbe; and lanes 5 and 7 were the Darbe standards 
(Catlin et al., 2002). This figure was copied from Catlin et al. (2002) with permissions from the American 
Association for Clinical Chemistry (1850 K Street, N.W., Suite 625, Washington, DC 20006-2113, 
permissions@aacc.org). 
 
The resolution of EPO isoforms on IEF gel can be enhanced by combining the 
conventional IEF approach with SDS-PAGE by the process of two-dimensional gel 
electrophoresis (2-DE). Since different isoforms of EPO and endogenous EPO showed 
different migration pattern on SDS gel, SDS-PAGE can be applied to solidify and confirm 
suspicious and ambiguous test results obtained from IEF analysis (Thevis et al., 2008). The 2-
DE method has been claimed to be able to separate recombinant proteins (Schlags et al., 
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2002).  Two-DE begins with IEF that separates the protein by pI through a pH gradient. Then, 
the protein analytes were separated in a direction 90 degrees from the first by SDS-PAGE. As 
a result, the protein analytes will be spread out across a 2-D surface rather than along a line. 
Three different commercial rhEPO isoforms (epoetin alfa, epoetin beta, and darbepoetin alfa) 
had been separated successfully by 2-DE; (Caldini et al, 2003).  
The problem with IEF and 2-DE is that the results generated by a scientist were hard 
to reproduce by a different scientist. Additionally, the IEF and 2-DE methods provide 
subjective results. Therefore, a more reproducible and less subjective method is needed to 
detect and differentiate the EPO isoforms. 
 
LC-MS TECHNIQUES USE IN EPO DRUG ANALYSES 
High performance liquid chromatography mass spectrometry (LC-MS) coupled with 
matrix assisted laser desorption / ionization-time of flight (MALDI-TOF) or electrospray 
ionization (ESI) has been applied to detect and identify EPO isoforms. The LC-MS methods 
use to analyze Darbe and rhEPO in blood samples were reproducible between different 
analysts, reliable, and generate less subjective results as compared to IEF and 2-DE. 
Scientists had been trying different attempts to develop a rugged LC-MS method to detect 
and differentiate the EPO isoforms. Earlier attempts applied sugar profiling method to detect 
EPO isoforms. Approximately 40% of the EPO molecule is glycans. The EPO isoforms are 
different from each other by their carbohydrate heterogeneity. Darbe and rhEPO were 
extracted from plasma samples by immunoaffinity precipitation. The glycans from the 
glycoproteins were cleaved by glycosidase enzymes and were identified by LC-MS by the 
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process of sugar profiling of the EPO isoforms. Another attempt was to isolate the EPO 
isoforms on agarose gels by SDS-PAGE and IEF. The isolated bands on the gel were 
analyzed by LC-MS to identify the EPO isoforms. Most recently, immunoaffinity separation 
has been applied to extract Darbe and rhEPO from plasma samples. The extract was cleaved 
with trypsin and analyzed by LC-MS to confirm and differentiate the EPO isoforms. 
 
Darbe and rhEPO analysis by sugar profiling using ESI-LC-MS 
Sugar profiling had been applied to identify EPO isoforms. Enzymes that target their 
glycans were used to cleave the branched carbohydrates from the glycoproteins. Since EPO 
isoforms are different in their carbohydrate heterogeneity, their differences can be determined 
by analyzing their glycan structures by LC-MS. Site specific carbohydrate mapping of rhEPO 
had been achieved by treatment of rhEPO with N-glycosidase F (PNGase F) and 
endoproteinase Glu-C enzymes followed by LC-MS (Kawasaki et al., 2000). Once the rhEPO 
was digested with enzymes to release the N-linked oligosaccharides and reduced with NaBH4 
to alditols, they were separated and characterized by ESI-LC-MS equipped with a graphitized 
carbon column (Kawasaki et al., 2000). By applying their method, they were able to 
determine the glycosylation sites, the site-specific carbohydrate heterogeneity of 
glycoproteins, and the carbohydrate structure.  
A selective glycoprotein mapping of rhEPO was employed for separation and 
detection of rhEPO glycoforms in structural analysis of carbohydrates at each glycosylation 
site (Ohta et al., 2001). The rhEPO was digested with endoproteinase Glu-C into nine 
peptides and four glycopeptides and eluted in the following order: N38, N24, O126, and N83 
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(Ohta et al., 2001). The glycoform in each glycopeptide was separated by differences in the 
number of sialic acid and N-acetyllactosaminyl repeats (Ohta et al., 2001). The glycans were 
analyzed by ESI-LC-MS with a Vydac C18 column eluted in acetonitrile and 1mM 
ammonium acetate, pH 6.8 (Ohta et al., 2001). By applying this method, 12, 16, and 22 
different N-linked oligosaccharides were determined at Asn 24, 38, and 83, respectively 
(Ohta et al., 2001). Two different O-linked oligosaccharides were detected at Ser126 (Ohta et 
al., 2001). 
Stubiger et al. (2005a) characterized the N- and O-glycan structures of rhEPO 
(epoetins-α and –β) and Darbe with enzymatic treatments of the EPO isoforms followed by 
MALDI-TOF-MS. The EPO isoforms were purified from plasma sample by immunoaffinity 
precipitation. For buffer exchange and further purification of protein samples, approximately 
400 µL of the eluted sample was transferred to a Nanosep Omega 3,000 membrane filter and 
centrifuged at 8,000  g (Stubiger et al., 2005a). After centrifugation, the volume was 
reconstituted with 400 µL of 60% IPA plus 0.1% formic acid solution (Stubiger et al., 
2005a). This step was repeated twice and with ultra-pure water at the last step (Stubiger et al., 
2005a). Approximately 100 to 200 µL of sample was recovered at the last step and 
lyophilized in eppendorf tubes (Stubiger et al., 2005a). Subsequently, this sample was 
reduced with dithiothreitol (DTT) and alkylated with carbamidomethylation to prevent from 
refolding of the glycoproteins by disulfide bond formation (Stubiger et al., 2005a). Then, the 
treated-samples were subjected to endoproteolytic digestion with trypsin and Glu-C (Stubiger 
et al., 2005a). The fragments were separated and fractionated with rp-C18 column and 
analyzed by MALDI-TOF-MS in a linear positive ion mode (Stubiger et al., 2005a).  By this 
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method, Stubiger and the team were able to differentiate the epoetin-α, epoetin-β, and Darbe 
by comparing their O-glycosylation patterns. 
 
Darbe and rhEPO analysis by sugar profiling using MALDI-LC-MS 
Stubiger et al. (2005b) investigated rhEPO (epoetins-α and –β) and Darbe on agarose 
gel and by matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) 
equipped with TOF mass analyzer operated in positive linear ion mode. The three EPO 
isoforms were successfully separated by SDS-PAGE and IEF (Stubiger et al., 2005b). Also, 
the different EPO isoforms were characterized by MALDI-MS only after de-N-glycosylation 
(removal of glycans) and de-sialyation (removal of sialic acids) of the glycoproteins by 
enzyme treatment (Stubiger et al., 2005b). Stubiger and the team found that the molecular 
masses of erythropoietins by gel-electrophoresis and mass spectrometry method were 
different. The masses determined by SDS-PAGE and IEF were 38 kDa for epoetins- α and –β 
and 49 kDa for Darbe (Stubiger et al., 2005b). In comparison, the molecular weight 
determined by MALDI-MS using internal calibration was approximately 30 kDa for epoetins- 
α and –β and 37 kDa for Darbe (Stubiger et al., 2005b). 
 
Darbe and rhEPO analysis by MALDI-LC-MS 
Gupta et al. (2005) described methods to screen, purify, separate, and confirm EPO 
isoforms from basal and spiked horse plasma samples. Horse plasma samples were collected 
and were centrifuged to separate blood plasma from red blood cells (Gupta et al., 2005). 
Darbe, rhEPO, and endogenous equine EPO were successfully extracted from positive and 
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spiked horse samples using rhEPO antibodies bound to Affi-gel of the immunoaffinity 
columns (Gupta et al., 2005). The eluted samples were run on polyacrylamide gels, stained, 
and EPO isoforms bands were collected (Gupta et al., 2005). Some of the collected EPO 
isoforms bands were subjected to in-gel deglycosylation and some were digested by trypsin 
(Gupta et al., 2005). Glycosylated and deglycosylated intact protein and the hydrolysis 
products (trypsin digest peptide fragments) were analyzed by MALDI-TOF MS-MS (Gupta et 
al., 2005). The intact mass ions for rhEPO and Darbe were 29,000 m/z and 26,000 m/z, 
respectively (Gupta et al., 2005). Their trypsin-hydrolysis products were m/z 2689 and 2359 
for rhEPO and m/z 2696 and 2293 for Darbe (Gupta et al., 2005). If peptide m/z and 
sequence matched authentic commercial synthesized EPO or Darbe peptides, then results will 
be positive and a violation reported. 
 
Darbe and rhEPO analysis by ESI-LC-MS 
Recently, Guan et al. (2007 & 2008) developed two LC-MS methods that 
unequivocally confirm and differentiate rhEPO and Darbe in equine plasma samples. These 
confirmation and differentiation methods were the focus of replication in this report. Since 
rhEPO, Darbe, and equine EPO are different in amino acid sequence homology, tryptic 
fragments (fragments generated by trypsin digestion of erythropoietins) that are unique to 
those glycoproteins can be used to confirm and differentiate the difference between rhEPO, 
Darbe, and eEPO in plasma samples (Guan et al., 2007 & 2008).  
In the confirmation method, plasma samples were used in their methods because the 
EPO concentration in plasma was found to be higher than in urine (Guan et al., 2007). To 
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purify the rhEPO and Darbe from plasma, approximately 2 mL of positive equine plasma was 
incubated with polyclonal antibodies coated magnetic beads for 16 to 24 hours at 37 oC 
(Guan et al., 2007). Polyclonal antibodies against rhEPO were used for the immuno-
separation process to separate rhEPO and Darbe from equine plasma because it was found 
that polyclonal anti-bodies had a higher recovery of the glycoproteins than monoclonal 
antibodies (Guan et al., 2007). After incubation, the glycoproteins were eluted from antibody-
coated magnetics beads (Guan et al., 2007). A buffer exchange was employed to further 
purify the eluted sample and to eliminate polyethylene glycol (PEG) introduced into sample 
during the immunoaffinity precipitation process because PEG can interfere with trypsin 
digestion (Guan et al., 2007). Subsequently, the recovered sample was reconstituted to 86 µL 
for trypsin digestion (Guan et al., 2007). Trypsin modified by reductive methylation was used 
in this method because it was resistant to autolytic digestion, eliminated chymotrypsin-like 
activity, and improved specificity (Guan et al., 2007). Normal trypsin would undergo 
autolysis that results in generation of pseudotrypsin with undesired chymotrypsin-like activity 
(Guan et al., 2007). For trypsin digestion, 86 µL of sample in 50 mM ammonium bicarbonate 
(NH4HCO3) and 10 µL of 20 µg per mL of trypsin were incubated at 37 oC for 3 hours. After 
3-hour incubation, 4 µL of 10% formic acid was added to the mixture to terminate trypsin 
digestion (Guan et al., 2007). The digested sample was analyzed by ESI-LC-MS for the 
tryptic fragments that were unique to the EPO isoforms (Guan et al., 2007).  
The sample preparation procedure of the differentiation method (Guan et al., 2008) is 
similar to the confirmation method (Guan et al., 2007) except for the following. In the 
confirmation method, a dual digestion method was used (Guan et al., 2008). After trypsin 
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digestion, the sample was further incubated at 80 oC for an additional of 10 minutes to 
deactivate trypsin (Guan et al., 2008). Then, the samples were further digested with 
glycosidase enzyme (PNGase F) because the glycosylations on the two tryptic fragments used 
to differentiate rhEPO and Darbe suppressed ionization of the mass detector (Guan et al., 
2008). After PNGase F digestion, 10 % formic acid was added into the sample to stop the 
PNGase enzyme digestion activities (Guan et al., 2008). In addition, 20% acetonitrile was 
added to the sample digest to increase solubility of the tryptic peptides in order to minimize 
the LC-MS carryover problem (Guan et al., 2008). The sample digest can be analyzed by ESI 
LC-MS (Guan et al., 2008). By analyzing the tryptic fragments that are unique to Darbe and 
rhEPO, Guan et al. and colleagues have successfully confirmed and differentiated the 
presence of rhEPO and Darbe in positive equine plasma samples.
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CHAPTER 3: MATERIALS AND METHODS 
 
Chemicals. The chemical information is also listed in the materials and methods sections of 
Guan et al. (2007) and Guan et al. (2008).  
• Epoetin Alfa was from Amgen Corp. (Thousand Oaks, CA), Lot P003478, Exp: 
10/04, 2000 Units per 1.0 mL. Each 1 mL vial (2000 units per mL) contains 2.5 mg or 
0.05% of Bovine Albumin Serum (BSA) in a pH 6.9 sterile buffer. One microgram 
(µg) of epoetin alfa is equivalent and equal to 200 units. This rhEPO was used as the 
standard for rhEPO analysis in this report because it was the only rhEPO standard 
available. 
• Darbepoetin alfa standards use in this study was donated by Guan et al. (2007) from 
the University Of Pennsylvania School Of Veterinary medicine. One microgram (µg) 
of Darbe is equivalent and equal to 800 units. The concentration of Darbe stock was 
at 20 µg/mL in water and stored at -80 oC until use.  
• The working standard solutions of rhEPO and Darbe were prepared by diluting the 
stocks with de-ionized water. 
• Purified rabbit IgG polyclonal anti-rhEPO antibody, catalog no. 286-EP, was from 
R&D systems (Minneapolis, MN).  
• Dynabeads M-280 tosylactivated magnetic beads, Cat. No. 142.04 at 2 x 109 beads 
per mL, was purchased from Invitrogen (Oslo, Norway). 
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• The following chemicals were purchased from Sigma Aldrich (Saint Louis, MO): 
Bradykinin fragment 2-9, polyethylene glycol 6000 (ultra grade), Igepal CA-630 for 
molecular biology, trizma hydrochloride (Reagent grade), and reagent grade bovine 
serum albumin (BSA). 
• Sequencing grade modified trypsin, Cat. No. V5111, was purchased from Promega 
(Madison, WI). Trypsin solution was prepared in 50 mM of bicarbonate buffer, pH 
7.8.  
• Peptide N-glycosidase F (PNGase F), Cat. No. P0704S at 15,000 units and 500,000 
units per mL, was purchased from New England BioLabs (Ipswich, MA). Working 
PNGase F solution was prepared fresh by mixing 4 µL of PNGase F stock solution 
(500,000 units per mL) into 96 µL of mixture solution. The mixture solution was 
made of 50 :50 (v/v) of glycerol and 5 mM Na2EDTA, 50 mM NaCl,  20 mM Tris-
HCl (pH 7.5). 
• The following were purchased from Fisher Scientific (Fair Lawn, New Jersey): 
acetonitrile (HPLC Grade); and formic acid, boric acid, sodium azide, ammonium 
bicarbonate, sodium chloride, Na2EDTA dihydrate, and Tris (hydroxymethyl) 
aminomethane were ACS grade. 
• Water use in this method was Millipore grade de-ionized water.  
• Buffers use for immunoaffinity purification, buffer exchange, and digestion of Darbe 
and rhEPO and for linkage of anti-rhEPO to magnetic beads were prepared according 
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to Guan et al. (2007 & 2008) references and according to the manufacturer’s manual 
from Invitrogen. They were as follow. 
• Buffer A (Phosphate buffer saline solution (PBS), pH 7.4).  
• Buffer B (0.1 M borate buffer (H3BO3), pH 9.5). 
• Buffer C (PBS, pH 7.4 plus 0.1% (w/v) BSA, 2 mM EDTA, and 0.02% (w/v) Na 
azide. 
• Buffer D (0.2 M Tris buffer pH 8.5 plus 0.1% (w/v) BSA). The washing buffer 
was 1% Igepal CA-630 in PBS (pH 7.4).  
• Elution buffer (0.1 % PEG 6000 in PBS, pH adjusted to 2.0 with concentrated 
HCl).  
• Exchange buffer (50 mM ammonium bicarbonate, pH 7.8.).  
• All buffers were stored at 8 oC. 
 
Devices. The Centricon centrifugal filter device with 30 kDa molecular weight (MW) cutoff 
that is listed in Guan et al. (2007) for buffer exchange has been discontinued and was 
replaced with a more updated filter device by Millipore, which was Amicon Ultra-4 with 
MW cutoff at 30 kDa, Cat. No. UFC800596. This new filter device was used in this study. 
The 0.22 micron Ultrafree-CL filter device, Cat. No. UFC40GV00, was purchased from 
Millipore Corp. (Bedford, MA). Dynal MPC-L magnetic particle concentrator was purchased 
from Invitrogen (Oslo, Norway). Labquake shaker (Barnstead / Thermolyne, model # 
400110), Sorvall Legen Mach 1.6 R centrifuge with fixed angel rotors (Thermo-Kendro 
Laboratory Products Inc., Asheville, NC), and Isotemp incubator (Fisher Scientific, Fair 
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Lawn, New Jersey) were purchased and used in this study. The heating block was purchased 
from Fisher Scientific (Fair Lawn, New Jersey), Cat. No. 11-718. 
 
Preparation of Sample.  The following procedures were described in Guan et al. (2007): 
linking of anti-rhEPO antibody to Dynal magnetic beads, immunoaffinity separation of Darbe 
and rhEPO from plasma, buffer exchange, and trypsin digestion of Darbe and rhEPO sample 
for T17 and T6 peptides. The dual digestion of Darbe and rhEPO by trypsin followed by 
PNGase F was listed in materials and methods section of Guan et al. (2008). The sample 
preparation was done in ambient temperature if temperature information was not indicated. 
 
Coating of anti-rhEPO antibody to magnetic beads. A homogeneous suspension of the 
Dynabeads was made by mixing with a pipette for approximately 1 minute. Immediately, 2 
mL of beads (Dynabeads M-280, Cat. No. 142.03 by Invitrogen) was transferred into a 5 mL 
plastic tube (Cat. No. T2076S by Argos Technologies). The tube was placed in the magnetic 
particle separator for 1 min to separate the solution from beads. The solution inside tube was 
discarded and the beads were saved. The tube was removed from the magnetic particle 
separator and 2 mL of buffer B was added into the tube. The capped tube was rotated for 
approximately 2 min in the Labquake shaker to wash the beads. After 2 min, the tube was 
removed from shaker and placed in the magnetic particle separator to separate beads from 
solution. The solution inside tube was discarded and another 2 mL of buffer B was added into 
the tube.  
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 One milligram (mg) of anti-rhEPO polyclonal antibody was mixed with 1 mL of 
buffer B. The beads suspended in 2 mL of buffer B was mixed with the 1 mL anti-rhEPO 
polyclonal antibody solution. The capped tube was placed in the shaker and rotated at 37 oC 
for 16 to 24 hours. After incubation, the tube was placed in the magnetic particle separator to 
discard the solution and the beads were saved as described earlier. Then, the antibody coated 
beads were washed with buffer C twice for 5 minutes each. After washing with buffer C, the 
coated beads were separated from solution in the magnetic particle separator. The solution 
inside tube was discarded and replaced with 2 mL of buffer D. The mixture was incubated at 
37 oC for 4 hours while rotating in the shaker. After 4 hours incubation, the coated beads 
were separated from solution in the magnetic particle separator. The solution inside the tube 
was discarded and replaced with 2 mL of buffer C. The capped tube was rotated for 5 minutes 
at room temperature. After 5 minutes, the tube was placed in the magnetic bead separator to 
separate the coated beads from solution. The solution inside tube was discarded and replaced 
with 2 mL of buffer C. The rhEPO antibody-coated beads solution was ready for use and was 
good for at least 8 months when stored at 5 oC. 
 
 
Extraction of rhEPO and Darbe from Equine Plasma. The anti-rhEPO antibody coated 
magnetic beads were washed with 2 mL of buffer C in the magnetic particle separator as 
described. After the beads were washed with buffer C, 400 µL of anti-rhEPO antibody coated 
magnetic beads were transferred into 2 mL of plasma in a 5 mL Argos plastic tube. The 
capped tube was placed in the shaker and rotated for 16 to 24 hours at 37 oC. 
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Elution of Darbe and rhEPO from antibody coated magnetic beads. After the 16 to 24 
hours incubation, the tube was removed from the shaker and centrifuged at 100  g for 1 
minute at 20 oC. The tube was placed in the magnetic particle separator to separate the beads 
from plasma. The plasma inside tube was discarded and replaced with 2 mL of washing 
buffer. The capped tube was placed in the shaker and rotated for 5 minutes at room 
temperature. After 5 minutes rotation, the tube was centrifuged at 100  g at 20 oC for 1 
minute. The tube was placed back into the magnetic particle separator to separate the beads 
from buffer. The solution inside tube was discarded and replaced with 2 mL of fresh washing 
buffer. This washing process was repeated 3 more times in order to wash the beads 
thoroughly. After the washing processes, the tube was placed in the magnetic particle 
separator to separate beads from buffer. The solution inside tube was discarded and beads 
were saved. Finally, 1 mL of elution buffer was added into tube to elute rhEPO and Darbe 
from the antibody coated magnetic beads. The capped tube was placed in the shaker and 
rotated for 30 minutes. After 30 minutes rotation, the tube was placed in the magnetic particle 
shaker to separate beads from solution. The solution was transferred into a 0.22 micron 
Ultrafree-CL filter device. The filter was centrifuged for 5 min at 2500  g at 20 oC. 
In the elution evaluation experiment, an addition of 2 mL of elution buffer was added 
into the tube and rotated for 15 minutes. The capped tube was placed in a magnetic particle 
separator to separate beads from solution. The solution inside tube was transferred into 0.22 
micron Ultrafree-CL filter device. The filter was centrifuged for 10 minutes at 2500  g at 20 
oC. 
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Buffer exchange procedure for the Guan et al. 2007 method. The filtered sample from the 
Ultrafree-CL filter device was transferred to an Amicon Ultra-4 filter device (MW cutoff at 
30 kDa, Cat. No. UFC800596) after centrifugation. The sample was centrifuged at 4,000  g 
for 10 minutes at 20 oC. Exchange buffer at 0.5 mL was added into the Amicon filter device 
and centrifuged for 5 minutes at 20 oC. This step was repeated 5 times. At the last buffer 
exchange cycle, the Amicon filter device was centrifuged at 4,000  g for 7 minutes or until 
the volume was below 86 µL. The retentate was transferred to a 1.5 mL plastic centrifuge 
tube. The volume was adjusted to 86 µL with exchange buffer as follow. The retentate 
volume was measured with a 100-µL Pipetman (Middleton, WI). The difference in volume 
was adjusted by adding exchange buffer to a final volume of 86 µL using the same pipet tip 
used for measuring the retentate. 
 
Buffer exchange procedure for the Guan et al. 2008 method. After centrifugation, the 
sample from the Ultrafree-CL filter device was transferred to an Amicon Ultra-4 filter device 
(MW cutoff at 30 kDa, Cat. No. UFC800596). The sample was centrifuged at 4,000  g for 
10 minutes at 20 oC. Exchange buffer at 0.5 mL was added into Amicon filter device and 
centrifuge for 5 minutes 20 at oC. This step was repeated 5 times. At the last buffer exchange 
cycle, the Amicon filter device was centrifuged at 4,000  g for 7 minutes or until the volume 
was below 81 µL. The retentate was transferred to a 1.5 mL plastic centrifuge tube. The 
volume was adjusted to 81 µL with exchange buffer as follow. The retentate volume was 
measured with a 100-µL pipet. The difference in volume was adjusted by adding exchange 
buffer to a final volume of 81 µL using the same pipet tip used for measuring the retentate. 
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Trypsin digestion of rhEPO and Darbe for the Guan et al. 2007 method. The 1.5 mL 
plastic centrifuge tube containing the retentate was transferred to a heating block at 80 oC for 
10 minutes to denature the proteins. After incubation the sample was removed from the 
heating block and cooled to room temperature. Exchange buffer at 100 µL was added in the 
original vial with 20 µg of trypsin and mixed by vortexing. Fifty µL of exchange buffer was 
added in the original vial with 20 µg of trypsin to double the trypsin concentration for trypsin 
concentration efficacy experiment and for the resulting (ISU) method modified from the 
Guan et al. 2007 and 2008 methods. Ten µL of trypsin solution was added into the 1.5 mL 
plastic centrifuge tube containing the denatured rhEPO and Darbe. The mixture was 
incubated at 37 oC for 3 hours for trypsin digestion. 
After 3 hours incubation, the sample was removed from the 80 oC incubator and 
cooled to room temperature. Four µL of 10% formic acid was added into the 1.5 mL plastic 
tube and mixed briefly to terminate digestion. The digest was immediately analyzed by LC-
MS/MS or stored at – 80 oC until use. 
 
Dual Digestion of rhEPO and Darbe Extract for the Guan et al. 2008 Method 
Trypsin digestion of rhEPO and Darbe. The 1.5 mL plastic centrifuge tube containing the 
retentate was transferred to a heating block at 80 oC for 10 minutes. This first incubation time 
varied for the incubation efficacy experiment and was 7 minutes for the resulting (ISU) 
method modified from the Guan et al. 2007 and 2008 methods. The sample was removed 
from the heating block and cooled to room temperature after the first incubation experiment. 
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One hundred µL of exchange buffer was added in the original vial with 20 µg of trypsin and 
mixed by vortexing. Fifty µL of exchange buffer was added in the original vial with 20 µg of 
trypsin to double the trypsin concentration for trypsin concentration efficacy experiment and 
for the resulting (ISU) method modified from the Guan et al. 2007 and 2008 methods. Ten 
µL of trypsin solution was added into the 1.5 mL plastic centrifuge tube containing the 
denatured rhEPO and Darbe. The mixture was incubated at 37 oC for 3 hours for trypsin 
digestion. 
PNGase F digestion of rhEPO and Darbe. After 3 hours incubation, the 1.5 mL plastic  
tube was transferred to the heating block at 80 oC for 10 minutes to deactivate trypsin. This 
second incubation time varies for incubation efficacy tests and was 5 minutes for the 
resulting (ISU) method modified from the Guan et al. 2007 and 2008 methods. The sample 
was removed from the 80 oC incubator and cooled to room temperature after incubation. Five 
µL of working PNGase F solution was added into the 1.5 mL plastic tube containing the 
tryptic digested sample. The 1.5 mL plastic tube was mixed briefly and incubated at 37 oC for 
1 hour. Four µL of 10% formic acid was added into the 1.5 mL plastic tube and mixed briefly 
to terminate digestion after incubation. Twenty µL of acetonitrile was added to the tube and 
mixed briefly. The digest was immediately analyzed by LC-MS/MS or stored at – 80 oC until 
use. 
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LC-MS/MS Analysis 
 
Instruments. A Finnigan LTQ-XL linear ion trap mass spectrometer with an electrospray 
ionization (ESI) source and with Xcalibur v 2.0 (Thermo Fisher Scientific) was used in this 
study. The mass spectrometer was connected to Accela autosampler and Accela pump 
(Thermo Fisher Scientific). 
 
LC separations 
The HPLC column was a wide-pore Zorbax 300 SB – C18, 50 x 1.0 mm I.D., 3.5 µM particle 
size attached to a Zorbax stable bond, 17 x 1.0 mm I.D., 5 µM guard column. The column 
temperature was at 26 oC. The LC mobile phase gradient use for the Guan et al. 2007 method 
was listed in Table 1. 
 
Table 1. LC mobile phase gradient for separation of T17 and T6 tryptic peptides from the Guan et al. 2007 
method. 
Time (min) Mobile phase A (%)a Mobile phase B (%)b 
Flow rate  
(µL/min) 
0 100 0 50 
1.0 100 0 50 
19.0 73 27 50 
19.5 20 80 50 
20.0 20 80 100 
23.0 20 80 100 
23.5 100 0 100 
28.0 100 0 100 
28.5 100 0 50 
29.0 100 0 50 
a
 Mobile phase A: Acetonitrile / deionized water / formic acid (5/95/0.1, v/v/v). 
b
 Mobile phase B: Acetonitrile / deionized water / formic acid (95/5/0.1, v/v/v). 
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The LC gradient method use for the Guan et al. 2008 method was listed in Table 2. 
Table 2. LC mobile phase gradient for separation of T9 and T5 tryptic peptides from the Guan et al. 2008 
method. 
Time (min) Mobile phase A (%)a Mobile phase B (%)b 
Flow rate  
(µL/min) 
0 100 0 50 
1.0 100 0 50 
23.0 67 33 50 
23.5 20 80 50 
24.0 20 80 100 
29.0 20 80 100 
29.5 100 0 100 
34.0 100 0 100 
34.5 100 0 50 
35.0 100 0 50 
a
 Mobile phase A: Acetonitrile / deionized water / formic acid (5/95/0.1, v/v/v). 
b
 Mobile phase B: Acetonitrile / deionized water / formic acid (95/5/0.1, v/v/v). 
 
The developed LC mobile phase gradient (ISU LC gradient) use to separate T17, T6, T9, and 
T5 peptides in one analysis was listed in Table 3. 
 
Table 3. LC mobile phase gradient (ISU gradient) use for separation of T17, T6, T9, & T5 for LC-MS/MS 
confirmation and differentiation of rhEPO and Darbe. 
Time (min) Mobile phase A (%)a Mobile phase B (%)b 
Flow rate  
(µL/min) 
0 100.0 0 50 
1.0 100.0 0 50 
25.0 73.0 27.0 50 
35.0 67.0 33.0 50 
35.5 20.0 80.0 50 
36.0 20.0 80.0 100 
41 20.0 80.0 100 
41.5 100.0 0 100 
15.0 100.0 0 100 
15.5 100.0 0 50 
46.0 100.0 0 50 
a
 Mobile phase A: Acetonitrile / deionized water / formic acid (5/95/0.1, v/v/v). 
b
 Mobile phase B: Acetonitrile / deionized water / formic acid (95/5/0.1, v/v/v). 
 
MS Analysis. The ionization mode was ESI positive. ESI source settings was initially tuned 
by syringe infusion of bradykinin fragment 2 to 9 at 1 µg/mL in 50:50:0.1 (v:v:v) of 
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acetonitrile, water, and formic acid. A mass of 453 m/z was used for optimization of gas 
flows. Then, the ESI parameter was adjusted to 4.7 kV for spray voltage, 20 for sheath gas 
flow, 10 for auxiliary gas flow, 1 for sweep gas flow, 6 volts for capillary voltage with 
capillary temperature at 275 oC, and 80 V for tube lens. The normalized collision energy was 
25 %. Isolation with was 1.5. Activation Q was 30 ms with wideband activation checked. The 
data acquisition parameters for LC-MS/MS of T17, T6, T9, and T5 in confirmation and 
differentiation of rhEPO and Darbe using the LC gradients in Tables 1, 2, and 3 were listed in 
Table 4. 
 
Table 4. MS/MS analysis of specific tryptic peptides. The information in this table was obtained from the Guan 
et al. 2007 & 2008. 
Peptides for confirmation of 
rhEPO & Darbe 
Peptides for differentiation of rhEPO & 
Darbe 
 
T17 T6 T9 T5 
Precursor Ions m/z 450.0 m/z 464.5 m/z 766.4 m/z 897.8 
Scan Range m/z 200-850 m/z 200-850 m/z 400-1200 m/z 700-1100 
Product Ions m/z 214, 714 
with S/N > 3 
m/z 235, 263, 
636 with S/N > 
3 
m/z 800.1, 857.6, 
963.6, 1020.1, 1055.8 
with S/N > 3 
m/z 460.3, 660.3, 
777.4, 965.6, 1015.9, 
1066.7, 1106.7, 
1115.6 with S/N > 3 
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CHAPTER 4: RESULTS 
 
Replication of the Guan et al. 2007 method 
In the process of replicating the Guan et al. 2007 method, Darbe standard was serially 
diluted to 400, 80, 16, 3.2, 0.64, and 0.128 ppb (ng/mL, where 0.2 unit = 1ng). These samples 
were analyzed according to the Guan et al. 2007 method (Figure 4). The 0.64 and 0.128 ppb 
Darbe standard samples were not detected for T17 and T6 peptides; therefore the lowest 
concentration detected for Darbe standard digest was determined to be 3.2 ppb for T17 and 
T6 peptides (Figure 4). The R-square (the square of a correlation coefficient) value calculated 
by Microsoft Excel software (Redmond, WA) for T17 and T6 peptides were one and 0.9992, 
respectively (Figure 4). The correlation coefficient is the estimate number of the correlation 
between two random variables (X and Y values) in a linear relationship. The integrated peak 
areas (PA) of T17 and T6 peptides increased as the Darbe concentrations increased from 3.2 
ppb to 400 ppb (Table 5). The average retention times for T17 and T6 peptides were 13.96 
and 17.18 minutes, respectively, with an infinite number for the signal-to-noise ratio (Table 
5).
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Figure 4. Darbe standard digest analyzed at 400, 80, 16, 3.2, 0.64, and 0.128 ppb (ng/mL, where 1 ng = 0.8 
unit) by the Guan et al. 2007 method. The samples were injected twice into the LC-MS. The data reported was 
the average of the two injections. The 0.64 and 0.128 ppb samples were not detected. The samples were 
analyzed by selected ion monitoring (SIM) of T17 (m/z 450) and T6 (m/z 464.5) peptide ions in MS/MS. PA is 
the integrated peak mass area of extracted ion chromatogram (EIC) detection in positive electrospray ionization 
(ESI+). Parts per billion = ppb. 
 
Table 5. Darbe standard digest at 400, 80, 16, 3.2, 0.64, and 0.128 ppb (ng/mL, where 1 ng = 0.8 unit) analyzed 
by the Guan et al. 2007 method. The 0.64 and 0.128 ppb samples were not detected. The samples were injected 
twice into the LC-MS. The data reported was the average of the two injections. The LC-MS analysis was by 
selected ion monitoring (SIM) of T17 (m/z 450) and T6 (m/z 464.5) peptide ions in MS/MS. PA is the 
integrated peak mass area of EIC in ESI+. Not detected = ND. Parts per billion = ppb. Signal-to-noise ration = 
S/N. Infinite = INF. 
Sample Description 
T17 
(min)  
T17  
(PA) 
T17 
(S/N) 
T6 
(min)  
T6  
(PA) 
T6 
(S/N) 
400 ppb Darbe standard digest 13.94 58680 INF 17.17 38008 INF 
80 ppb Darbe standard digest 13.91 10737 INF 17.20 5937 INF 
16 ppb Darbe standard digest 13.97 2254 INF 17.22 1270 INF 
3.2 ppb Darbe standard digest 14.02 558 INF 17.15 233 INF 
0.64 ppb Darbe standard digest ND ND ND ND ND ND 
0.128 ppb Darbe standard digest ND ND ND ND ND ND 
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Darbe spiked equine plasma samples at 0.1, 0.2, 0.5, 1.0, and 2.5 ppb and negative 
control plasma were analyzed by the Guan et al. 2007 method (Figure 5 and Table 6). The 
negative plasma control sample had no detection of T17 and T6 peptide ions (Table 6). The 
Darbe spiked plasma samples from 0.1 to 2.5 ppb detected of T17 and T6 peptide ions 
(Figure 5 and Table 6). The lowest concentration of Darbe detected in spiked plasma by LC-
MS was 0.1 ppb (ng/mL, where 1ng = 0.8 unit) with the R-square values calculated to be 
0.9902 and 0.9858 for T17 and T6 peptides, respectively (Table 6 and Figure 5). The signal-
to-noise ratio is the intensity of the compound detected divided by the intensity of the noise. 
The proposed criteria from Guan et al. 2007 and 2008 literatures was that the signal-to-noise 
ratio of the detected compound must be greater than 3 in order for the detected peak mass 
area to be used for confirmatory purpose. The signal-to-noise ratio from the current work was 
8 and greater (Table 6). The mobile phase A injected into LC-MS had no detection of T17 
and T6 peptide ions (Table 6). 
In the same experiment, the Darbe spiked plasma samples were eluted the second 
times with 2 mL of elution buffer and analyzed by the Guan et al. 2007 method (Table 6). 
The Darbe samples eluted the second time for the 0.1 to 0.5 ppb and the negative control 
plasma samples were not detected of the presence of the compounds by LC-MS (Table 6). 
The integrated peak mass areas of the 1 ppb Darbe-spiked plasma samples for the T17 and T6 
peptides were 2103 and 1031, respectively, for the first elution, and 11.09 and 17.64, 
respectively, for the second elution (Table 6). The integrated peak mass areas of the 2.5 ppb 
Darbe-spiked plasma samples for the T17 and T6 peptides were 6460 and 3191, respectively, 
for the first elution, and 81.9 and 78.3, respectively, for the second elution (Table 6).  The 
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amount of Darbe eluted in the second elution was low as compared to the first elution for the 
1 ppb and 2.5 ppb spiked-plasma samples (Table 6). Therefore, the first elution process of the 
Guan et al. 2007 method was sufficient to extract Darbe from the anti-rhEPO antibody coated 
magnetic beads (Table 6).  
 
y = 212.17x2 + 1993.8x + 128.37
R2 = 0.9902
T17
y = 180.71x2 + 729.65x + 228.22
R2 = 0.9858
T6
0
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3000
4000
5000
6000
7000
0 0.5 1 1.5 2 2.5
Plasma Concentration (ppb)
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T17 Area
T6 Area
Poly. (T17 Area)
Poly. (T6 Area)
 
Figure 5. Darbe spiked plasma at 0.1, 0.2, 0.5, 1.0, and 2.5 ppb (ng/mL, where 1 ng = 0.8 unit) analyzed by the 
Guan et al. 2007 method. The signal-to-noise ratio for the detected samples was 8 or greater. The samples were 
analyzed by selected ion monitoring (SIM) of T17 (m/z 450) and T6 (m/z 464.5) peptide ions in MS/MS 
according to the Guan et al. 2007 method. PA is the integrated peak (mass) area of EIC in ESI+. Parts per 
billion = ppb. 
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Table 6. Darbe spiked plasma samples were analyzed the Guan et al. 2007 method. The LC-MS was in selected 
ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5) peptide ions in MS/MS. The first set of data was the 
first extraction procedure with 1 mL of eluent to elute rhEPO/Darbe from antibody coated beads. The data was 
plotted in Figure 2. The second set of data was the second extraction with 2 mL of eluent. PA and S/N are the 
integrated peak area and signal-to-noise ratio of EIC in ESI+, respectively, of the tryptic peptides. INF means 
infinite. 
Sample Description 
RT 
(min) 
T17 
(PA) 
T17 
(S/N) 
RT 
(min) 
T6 
(PA) 
T6 
(S/N) 
Mobile phase A ND ND N/A ND ND N/A 
Negative Control plasma  ND ND N/A ND ND N/A 
0.1 ppb Darbe-spiked plasma  14.47 215 8 17.49 322 INF 
0.2 ppb Darbe-spiked plasma  14.41 444 22 17.45 238 INF 
0.5 ppb Darbe-spiked plasma  14.39 1595 65 17.46 861 INF 
1.0 ppb Darbe-spiked plasma 14.52 2103 98 17.53 1031 INF 
2.5 ppb Darbe-spiked plasma  14.42 6460 661 17.67 3191 INF 
Mobile phase A ND ND N/A ND ND N/A 
Negative Control spiked 
plasma 2nd ext. w/ 2 mL 
eluent  
ND ND N/A ND ND N/A 
0.1 ppb Darbe-spiked plasma 
2nd ext. w/ 2 mL eluent ND ND N/A ND ND N/A 
0.2 ppb Darbe-spiked plasma 
2nd ext. w/ 2 mL eluent ND ND N/A ND ND N/A 
0.5 ppb Darbe-spiked plasma 
2nd ext. w/ 2 mL eluent ND ND N/A ND ND N/A 
1.0 ppb Darbe-spiked plasma 
2nd ext. w/ 2 mL eluent 14.09 11.09 INF 17.64 34.38 INF 
2.5 ppb Darbe-spiked plasma 
2nd ext. w/ 2 mL eluent 14.4 81.9 INF 17.32 78.3 INF 
 
Figures 6 and 7 described LC-MS extracted ion chromatograms (EIC) of 1 ppm Darbe 
and 2 ppm rhEPO standard samples, respectively, analyzed by the Guan et al. 2007 method. 
The T17 and T6 peptides were detected for Darbe and rhEPO samples (Figures 6 and 7). The 
selected product ions for T17 were m/z 235, 263, and 636. The selected product ions for T6 
were 214 and 714. The retention times for T17 peptides for Darbe and rhEPO samples were 
14.88 and 14.76 minutes, respectively (Figures 6 and 7). The retention times for T6 peptides 
for Darbe and rhEPO samples were 17.94 and 17.93 minutes, respectively (Figures 6 and 7). 
The T17 and T6 peptides had a good signal-to-noise ratio for the peaks (Figures 6 and 7). 
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Figure 6. EIC of 1 part per million (ppm) Darbe standard analyzed by the Guan et al. 2007 method. T17 peptide is on the top and T6 peptide is on the 
bottom of the chromatogram. The left side of chromatogram showed the retention time of the peptide fragments. The right side of chromatogram 
showed the product ions by MS/MS that are unique to the peptide fragments.  The sample was analyzed by LC-MS ESI+ in selected ion monitoring 
(SIM) of T17 (m/z 450) and T6 (m/z 464.5) peptide ions in MS/MS. RT = retention time. MA = integrated peak (mass) area. SN = signal-to-noise 
ratio. Parts per million = ppm. 
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Figure 7.  EIC of 2 parts per million (ppm) rhEPO standard analyzed by the Guan et al. 2007 method. T17 peptide is on the top and T6 peptide is on 
the bottom of the chromatogram. The left side of chromatogram showed the retention time of the peptide fragments. The right side of chromatogram 
showed the product ions by MS/MS that are unique to the peptide fragments.  The sample was analyzed by LC-MS ESI+ in selected ion monitoring 
(SIM) of T17 (m/z 450) and T6 (m/z 464.5) peptide ions in MS/MS. RT = retention time. MA = integrated peak mass area. SN = signal-to-noise 
ratio. 
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 The published results from Guan et al. 2007 were compared to the results replicated 
in the current work (denoted as ISU) analyzed by the Guan et al. 2007 method (Table 7). The 
retention times and product ions of T17 and T6 peptides from the current work were similar 
to the results from the published work of Guan et al. 2007 for the rhEPO and Darbe samples 
analyzed by the Guan et al. 2007 method (Table 7). The LOD for the Darbe spiked equine 
plasma of the current work was identical to the published results from Guan et al. 2007 for 
T17 and T6 peptides (Table 7). The LOD of rhEPO from the published results of Guan et al. 
2007 was 0.1 ppb for T17 and T6 peptides (Table 7). The LOD of rhEPO from the current 
work was listed as not applicable because a valid rhEPO standard was not available during 
the time of analysis (Table 7). 
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Table 7. The results of the current work by the Guan et al. 2007 method and the Guan et al. 2007 published 
results comparison. The LOD values listed were from spiked plasma. The value in parts per billion (ppb) is 
ng/mL with mass-to-unit conversion for rhEPO (1 ng = 0.2 unit) and Darbe (1 ng = 0.8 unit). Admin means 
administration sample. N/A = not available. The results of current work are denoted as ISU (Iowa State 
University). 
Sample Description Fragment 
aMolecular Ion 
[M+2H]2+ Status 
RT 
(min) 
bProduct Ions 
Identified 
LOD 
(ppb) 
Darbe spiked plasma 
from Guan et al. 2007 T6 m/z 464.5 Detected 13.34 
m/z 214, 714 
with S/N > 3 0.1 
Darbe spiked plasma  
(ISU) T6 m/z 464.5 Detected 
c14.44 m/z 214, 714 
with S/N > 3 0.1 
Darbe spiked plasma 
from Guan et al. 2007 T17 m/z 450.0 Detected 17.59 
m/z 235, 263, 
636 with S/N > 3 0.1 
Darbe spiked plasma 
(ISU) T17 m/z 450.0 Detected 
c17.52 m/z 235, 263, 636 with S/N > 3 0.1 
rhEPO admin plasma  
from Guan et al. 2007 T6 m/z 464.5 Detected 17.92 
m/z 214, 714 
with S/N > 3 0.1 
rhEPO standard 
digestion (ISU) T6 m/z 464.5 Detected 17.93 
m/z 214, 714 
with S/N > 3 N/A 
rhEPO admin plasma 
from Guan et al. 2007 T17 m/z 450.0 Detected 15.59 
m/z 235, 263, 
636 with S/N > 3 0.1 
rhEPO standard 
digestion (ISU) T17 m/z 450.0 Detected 14.76 
m/z 235, 263, 
636 with S/N > 3 N/A 
aDarbe and rhEPO was analyzed by LC-MS ESI+ in selected ion monitoring (SIM) of T17 (m/z 450) and T6 
(m/z 464.5) peptide ions. 
bThe product ions were generated by MS/MS of the molecular ion. 
cThe retention time (RT) was averaged of all injections from 0.1 to 2.5 ppb listed in Figure 5. 
 
 
Replication of the Guan et al. 2008 method 
In replication of the Guan et al. 2008 method, 1 ppm Darbe standard and 2 ppm 
rhEPO  standard solutions were prepared from standard stock solutions. The samples were 
prepared by the dual digestion procedure and analyzed according to the Guan et al. 2008 
method (Figures 8 and 9). Only the T5 peptide ion could be detected for the rhEPO sample 
(Figure 8). The T9 peptide ion was not detected for the rhEPO sample (Figure 8). The T5 
peptide ion was not detected for the Darbe sample (Figure 9). Only the T9 peptide ion was 
detected for the Darbe sample (Figure 9). 
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Figure 8.  EIC of 2 ppm rhEPO standard analyzed by the Guan et al. 2008 method. The top of chromatogram is selected to detect Darbe for T9 
peptide ion. The bottom portion of chromatogram is selected to detect rhEPO for T5 peptide ion. The left side of chromatogram showed the 
retention time of the peptide fragments. The right side of chromatogram showed their unique product ions by MS/MS. The sample was analyzed by 
selected ion monitoring (SIM) of T9 (m/z 766.4) & T5 (m/z 897.8) peptide ions in MS/MS. RT = retention time. MA = integrated peak mass area. 
SN = signal-to-noise ratio. INF = infinite. 
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Figure 8. EIC of 1 ppm Darbe standard analyzed by the Guan et al. 2008 method. The top of chromatogram is selected to detect Darbe for T9 peptide 
ion. The bottom portion of chromatogram is selected to detect rhEPO for T5 peptide ion. The left side of chromatogram showed the retention time of 
the peptide fragments. The right side of chromatogram showed their unique product ions by MS/MS. The sample was analyzed by selected ion 
monitoring (SIM) of T9 (m/z 766.4) & T5 (m/z 897.8) peptide ions in MS/MS. RT = retention time. MA = integrated peak mass area. SN = signal-to-
noise ratio. INF = infinite. 
 
C:\Xcalibur\data\120407b\LTX120407A3 12/4/2007 8:25:57 PM 1.0 ppm DPO STD dig new Penn meth 12/04/07
ZBX300SB-C18:1x50mm;5to30in20@50 ul/min
RT: 18.00 - 22.00 SM: 7B
18.0 18.5 19.0 19.5 20.0 20.5 21.0 21.5 22.0
Time (min)
0
10
20
30
40
50
60
70
80
90
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
RT: 20.52
MA: 907324
SN: 4323
20.56
20.88 21.10 21.4719.9519.7619.2018.6918.16
NL: 7.50E4
m/z= 
799.60-800.60+857.10-858.10+
963.10-964.10+1019.60-1020.60+
1055.30-1056.30 F: ITMS + c ESI w  
Full ms2 766.40@cid25.00 
[700.00-1100.00]  MS LTX120407A3
LTX120407A3 #3125-3169 RT: 20.45-20.64 AV: 45 NL: 2.23E4
F: ITMS + c ESI w  Full ms2 766.40@cid25.00 [700.00-1100.00]
700 750 800 850 900 950 1000 1050 1100
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
963.82907.14
857.63
1020.38
1055.76
800.13
898.16848.69 954.69713.05 1046.74 1082.541011.26739.44 784.38
RT: 16.00 - 18.00
16.0 16.5 17.0 17.5 18.0
Time (min)
0
10
20
30
40
50
60
70
80
90
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
16.75
16.77
NL: 2.58
m/z= 
459.80-460.80+659.80-660.80+776.90-777.90+
965.10-966.10+1015.40-1016.40+
1066.20-1067.20+1106.20-1107.20+
1115.10-1116.10 F: ITMS + c ESI w  Full ms2 
897.80@cid25.00 [400.00-1200.00]  MS 
LTX120407A3
LTX120407A3 #2544 RT: 16.75 AV: 1 NL: 0
F: ITMS + c ESI w  Full ms2 897.80@cid25.00 [400.00-1200.00]
400 500 600 700 800 900 1000 1100 1200
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
T9 peptide ion 
T5 peptide ion not detected 
T5 product ions by 
MS/MS not detected 
T5 product ions 
by MS/MS 
 43 
The rhEPO stock solution was serially diluted to 2 ppm, 400 ppb, 100 ppb, 20 ppb, 
and 10 ppb (ng/mL, with 1 ng = 0.2 unit) with de-ionized water (Table 8). The Darbe stock 
solution was also serially diluted to 0.1, 0.2, 0.5, 1.0, and 2.5 ppb (ng/mL, with 1 ng = 0.8 
unit) with de-ionized water (Table 8). The diluted Darbe and rhEPO standard samples were 
analyzed by the Guan et al. 2008 method (Table 8). The lowest detection of Darbe standard 
sample was determined to be 2.5 ppb (Table 8). The 1.0 ppb and below Darbe standard 
samples were not detected (Table 8). Only the concentrations at 100 ppb and above were 
detectable for rhEPO standard dual digested samples (Table 8). The 20 ppb and 10 ppb 
samples were not detected (Table 8).
 44 
Table 8. Darbe standard and rhEPO standard samples analyzed by the Guan et al. 2008 method. Each sample 
was injected twice into the LC-MS. Therefore, the data presented is in duplicates. The dual digest samples were 
analyzed by LC-MS in selected ion monitoring (SIM) of T9 (m/z 766.4) & T5 (m/z 897.8) peptide ions in 
MS/MS. PA and S/N are the integrated peak mass area and signal-to-noise ratio of EIC in ESI+, respectively, of 
the tryptic peptides. INF means infinite. ND = not detected. N/A = not applicable. 
Sample Description 
RT 
(min) 
T5 
(PA) 
T5 
(S/N) 
RT 
(min) 
T9 
(PA) 
T9 
(S/N) 
0.1 ppb Darbe standard dual digest ND ND N/A ND ND N/A 
0.1 ppb Darbe standard dual digest ND ND N/A ND ND N/A 
0.2 ppb Darbe standard dual digest ND ND N/A ND ND N/A 
0.2 ppb Darbe standard dual digest ND ND N/A ND ND N/A 
0.5 ppb Darbe standard dual digest ND ND N/A ND ND N/A 
0.5 ppb Darbe standard dual digest ND ND N/A ND ND N/A 
1.0 ppb Darbe standard dual digest ND ND N/A ND ND N/A 
1.0 ppb Darbe standard dual digest ND ND N/A ND ND N/A 
2.5 ppb Darbe standard dual digest ND ND N/A 19.89 1012 INF 
2.5 ppb Darbe standard dual digest ND ND N/A 19.99 1013 INF 
10 ppb rhEPO standard dual digest ND ND N/A ND ND N/A 
10 ppb rhEPO standard dual digest ND ND N/A ND ND N/A 
20 ppb rhEPO standard dual digest ND ND N/A ND ND N/A 
20 ppb rhEPO standard dual digest ND ND N/A ND ND N/A 
100 ppb rhEPO standard dual digest 16.28 309 INF ND ND N/A 
100 ppb rhEPO standard dual digest 16.27 304 INF ND ND N/A 
400 ppb rhEPO standard dual digest 16.38 8008 INF ND ND N/A 
400 ppb rhEPO standard dual digest 16.3 7580 INF ND ND N/A 
2 ppm rhEPO standard dual digest 16.44 97661 INF ND ND N/A 
2 ppm rhEPO standard dual digest 16.4 79178 INF ND ND N/A 
 
An experiment was conducted to investigate into the cause of poor LC-MS detection 
of rhEPO standard dual digest samples (Table 8). The Darbe stock solution was diluted in 
exchange buffer (50 mM ammonium bicarbonate, pH 7.8) with and without BSA to 2.5 ppb 
(Table 9). The rhEPO stock solution was diluted with exchange buffer to 2.5 ppb. The diluted 
samples were analyzed by the Guan et al. 2008 method (Table 9). 
The T9 peptide ion for confirmation of Darbe was detected in the 2.5 ppb Darbe standard 
without BSA in sample (Table 9). The T5 peptide ion for the identification of rhEPO was not 
detected in the all of the 2.5 ppb Darbe standard samples. The 2.5 ppb Darbe standard with 
BSA in the sample had no detection of the T9 peptide ion (Table 7). The expected T5 peptide 
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ion was not detected in the 2.5 ppb rhEPO standard dual digest sample (Table 7). Therefore, 
the poor LC-MS detection of the rhEPO standard dual digest samples (Table 8) was caused 
by BSA in the rhEPO stock solutions (Table 9). BSA may interfere with trypsin digestion 
activity resulting in no detection of the peptides for the Darbe sample with BSA (Table 9) 
and the rhEPO standard sample (Tables 8 and 9). 
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Table 9.  Efficacy of Bovine Albumin Serum (BSA) in Darbe and rhEPO samples investigation. The samples 
were analyzed by the Guan et al. 2008 method. Each dual digest sample was injected twice into the LC-MS. 
Therefore, the data presented is in duplicates. LC-MS analysis was in selected ion monitoring (SIM) of T9 (m/z 
766.4) & T5 (m/z 897.8) peptide ions in MS/MS. PA and S/N are the integrated peak mass area and signal-to-
noise ratio of EIC in ESI+, respectively, of the tryptic peptides. INF means infinite. RT = retention time in 
minutes. 
Sample Description 
T9 RT 
(min) T9 (PA) 
T9 
(S/N) 
T5 RT 
(min) T5 (PA) 
T5 
(S/N) 
2.5 ppb Darbe standard dual 
digestion (No BSA) 24.63 2322 21 ND ND N/A 
2.5 ppb Darbe standard dual 
digestion (No BSA) 24.42 1565 13 ND ND N/A 
2.5 ppb Darbe standard with 
0.05% BSA dual digestion ND ND N/A ND ND N/A 
2.5 ppb Darbe standard with 
0.05% BSA dual digestion ND ND N/A ND ND N/A 
2.5 ppb rhEPO standard dual 
digestion ND ND N/A ND ND N/A 
2.5 ppb rhEPO standard dual 
digestion ND ND N/A ND ND N/A 
 
The published results from Guan et al. 2008 were compared to the results from the 
current work (denoted as ISU) ISU in the replication of the Guan et al. 2008 method (Table 
10). The product ions of T9 and T5 peptides from the current work (ISU) were identified to 
be similar to the published results from Guan et al. 2008 for rhEPO and Darbe (Table 10). 
The retention times of T9 and T5 peptides from the current work were comparable to the 
published results from Guan et al. 2008 for rhEPO and Darbe (Table 10).  The LOD for the  
Darbe spiked equine plasma from the current work was identical to the published results from 
Guan et al. 2008 for T9 and T5 peptides (Table 10). The LOD of rhEPO from the published 
work of Guan et al. 2008 was 0.1 ppb for T9 and T5 peptides (Table 10). The LOD of rhEPO 
for the current work was listed as not applicable because a valid rhEPO standard was not 
available during the time of analysis (Table 10). 
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Table 10.  The results of the current work by the Guan et al. 2008 method and the Guan et al. 2008 published 
results comparison.. The LOD values listed were from standard dual digest. The value in parts per billion (ppb) 
is ng/mL with mass-to-unit conversion for rhEPO (1 ng = 0.2 unit) and Darbe (1 ng = 0.8 unit). N/A = not 
available. The results of current work are denoted as ISU (Iowa State University). 
Sample Description Fragment 
aMolecular 
Ion 
[M+2H]2+ Status 
RT 
(min) 
bProduct Ions 
Identified 
cLOD 
(ppb) 
Darbe standard digestion 
from Guan et al. 2008 T5 m/z 897.8 ND ND ND N/A 
Darbe standard digestion 
(ISU) T5 m/z 897.8 ND ND ND N/A 
Darbe standard digestion 
from Guan et al. 2008 T9 m/z 766.4 Detected 17.89 
m/z 800.1, 857.6, 
963.5, 1020.3, 
1055.6 with S/N > 
3 
0.05 
Darbe standard digestion 
(ISU) T9 m/z 766.4 Detected 20.52 
m/z 800.1, 857.6, 
963.6, 1020.4, 
1055.8 with S/N > 
3 
d0.05 
rhEPO standard 
digestion from Guan et 
al. 2008 
T5 m/z 897.8 Detected 14.39 
m/z 460.3, 660.3, 
777.4, 965.6, 
1015.9, 1066.7, 
1106.7, 1115.6 
with S/N > 3 
0.1 
rhEPO standard 
digestion (ISU) T5 m/z 897.8 Detected 17.05 
m/z 460.3, 660.4, 
777.4, 965.9, 
1015.9, 1066.8, 
1106.8, 1115.9 
with S/N > 3 
N/A 
rhEPO standard 
digestion from Guan et 
al. 2008 
T9 m/z 766.4 ND ND ND N/A 
rhEPO standard 
digestion (ISU) T9 m/z 766.4 ND ND ND N/A 
aDarbe and rhEPO was analyzed by selected ion monitoring (SIM). 
bThe product ions were generated by MS/MS of the molecular ion. 
cThe LOD values were from spiked plasma samples. 
dThe LOD value was from Figure 16. 
 
 
Development of LC mobile phase gradient method 
Two parts per million rhEPO and 25 ppb Darbe standard samples were prepared by 
diluting stock solutions with de-ionized water. A new LC mobile phase gradient (ISU 
gradient) was developed (Table 3) to separate the combined four tryptic peptide fragments (T 
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17, T6, T9, & T5) from rhEPO and Darbe plasma samples in one analysis. The diluted 
samples were analyzed by the Guan et al. 2008 substituted with the (ISU) developed HPLC 
gradient method (Figures 10 and 11).  The T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4), 
and T5 (m/z 897.8) peptide ions were separated and detected for Darbe and rhEPO standard 
dual digested samples (Figures 10 and 11). The product ions of the T17, T6, T9, and T5 
peptide ions were identified to be similar to the Guan et al. 2008 method (Figures 10 and 11). 
The selected T5 (m/z 897.8) peptide ion for confirmation of rhEPO was detected in rhEPO 
dual digested sample (Figure 10). On the other hand, the selected T9 peptide ion for 
confirmation of Darbe was not detected in rhEPO dual digest sample (Figure 10).  The 
selected T9 (m/z 766.4) peptide ion was detected and selected T5 peptide ion was not 
detected in Darbe dual digested sample (Figure 11). 
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Figure 10. EIC of 2 ppm rhEPO standard analyzed by the Guan et al. 2008 substituted with the (ISU) developed HPLC gradient method. The left side 
of the chromatogram showed the retention time and peak mass areas of the peptides. The right side of the chromatogram showed the selected product 
ions of the peptides. The sample was analyzed by LC-MS ESI+ in selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4), & 
T5 (m/z 897.8) peptide ions in MS/MS. RT = retention time. MA = integrated peak mass area. SN = signal-to-noise ratio. INF = infinite. 
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Figure 11.  EIC of 25 ppb Darbe standard analyzed by the Guan et al. 2008 substituted with the (ISU) developed HPLC gradient method. The left 
side of the chromatogram showed the retention time and peak mass areas of the peptides. The right side of the chromatogram showed the selected 
product ions of the peptides. The sample was analyzed by LC-MS ESI+ in selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 
(m/z 766.4), & T5 (m/z 897.8) peptide ions in MS/MS. RT = retention time. MA = integrated peak mass area. SN = signal-to-noise ratio. INF = 
infinite. 
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Darbe spiked plasma samples at concentrations of 1.0, 2.5, 5.0, and 25 ppb were 
analyzed by the Guan et al. 2008 substituted with the (ISU) developed HPLC gradient  
method (Figure 11 and Table 11). The average retention times for T17, T6, and T9 peptides 
were 15.8, 20.4, and 24.2 minutes, respectively (Table 11). The signal-to-noise ratio was ten 
or greater for all of the peptides (Table 11). The T5 peptide ion was not detected for all the 
Darbe spiked plasma samples (Table 11). None of the peptides were detected the negative 
control plasma sample (Table 11). The R-square values calculated by Microsoft Excel 
software (Redmond, WA) for T17, T6, & T9 peptides were 0.9998, 0.9991, and 0.9977, 
respectively (Figure 12). 
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Table 11. Darbe spiked and negative control plasma samples analyzed by the Guan et al. 2008 substituted with 
the (ISU) developed HPLC gradient  method. Each sample was injected twice into the LC-MS. Therefore, the 
data presented is in duplicates. The dual digest samples were analyzed by LC-MS in selected ion monitoring 
(SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4) & T5 (m/z 897.8) peptide ions in MS/MS. PA and S/N 
are the integrated peak mass area and signal-to-noise ratio of EIC in ESI+, respectively, of the tryptic peptides. 
ND = not detected. N/A = not applicable. Negative control = neg ctrl. 
Sample Name 
T17 
RT 
(min) 
T17 
(PA) 
T17 
(S/N) 
T6 
RT 
(min) 
T6 
(PA) 
T6 
(S/N
) 
T9 
RT 
(min) 
T9 
(PA) 
T9 
(S/N) 
T5 
RT 
(min) 
T5 
(PA) 
T5 
(S/N) 
Neg Ctrl 
plasma  ND ND N/A ND ND N/A ND ND N/A ND ND N/A 
Neg Ctrl 
plasma  ND ND N/A ND ND N/A ND ND N/A ND ND N/A 
1.0 ppb 
Darbe-spiked 
plasma 
15.71 1488 INF 20.45 792 INF 24.02 1641 10 ND ND N/A 
1.0 ppb 
Darbe-spiked 
plasma 
15.76 1036 INF 20.47 911 INF 24.09 13305 10 ND ND N/A 
2.5 ppb 
Darbe-spiked 
plasma 
15.79 7216 INF 20.50 2808 INF 24.14 44756 23 ND ND N/A 
2.5 ppb 
Darbe-spiked 
plasma 
15.80 7128 INF 20.30 2556 INF 24.19 40678 22 ND ND N/A 
5.0 ppb 
Darbe-spiked 
plasma 
15.74 15800 INF 20.42 5616 INF 24.23 84490 41 ND ND N/A 
5.0 ppb 
Darbe-spiked 
plasma 
15.86 16368 INF 20.42 5849 INF 24.17 87551 58 ND ND N/A 
25 ppb Darbe-
spiked plasma 15.78 42204 INF 20.45 13726 INF 24.20 202892 115 ND ND N/A 
25 ppb Darbe-
spiked plasma 15.70 41886 INF 20.50 14162 INF 24.38 203261 119 ND ND N/A 
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Figure 12. Darbe spiked plasma samples from 1 to 25 ppb were analyzed by the Guan et al. 2008 substituted 
with the (ISU) developed HPLC gradient  method. The samples were analyzed by LC-MS ESI+ in selected ion 
monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4) & T5 (m/z 897.8) peptide ions in MS/MS. 
PA is the integrated peak mass area of EIC for T17, T6, and T9 tryptic peptides. 
 
 
Reproducibility of the Guan et al. 2008 method 
The second and third 2.5 ppb Darbe-spiked plasma samples in Table 12 were 
prepared and analyzed together by the Guan et al. 2008 substituted with the (ISU) developed 
HPLC gradient  method. The first 2.5 ppb Darbe-spiked plasma sample in Table 12 was 
analyzed, in a separate analysis, by the Guan et al. 2008 substituted with the (ISU) developed 
HPLC gradient  method . Each of the samples was injected twice into the LC-MS and the 
data of two injections were averaged. The reproducibility of the three samples was 
determined by retention times and integrated peak mass areas comparison. The retention 
times generated for T17, T6, and T9 peptides were similar in the three analyses (Table 12). 
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The peak areas generated for the peptides varied between each sample with an average 
percent relative standard deviation of close to 20% (Table 12). 
 
Table 12. The 2.5 ppb Darbe-spiked plasma samples were analyzed by the Guan et al. 2008 substituted with the 
(ISU) developed HPLC gradient  method. The samples were analyzed by LC-MS ESI+ in selected ion 
monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4) & T5 (m/z 897.8) peptide ions in MS/MS. 
The data presented was the average of two LC-MS injections. PA is the integrated peak mass area of EIC for 
T17, T6, and T9 tryptic peptides. AVG = average, STDEV = standard deviation, and RSD = relative standard 
deviation. 
Sample Name 
T17 RT 
(min) 
T17 
(PA) 
 T6 RT 
(min) T6 (PA) 
T9 RT 
(min) T9 (PA) 
  
       
2.5 ppb Darbe-spiked plasma 
sample 15.80 7172 20.40 2682 24.17 42717 
         
2.5 ppb Darbe-spiked plasma 
sample 16.42 8541 20.76 3520 24.41 28283 
  
       
2.5 ppb Darbe-spiked plasma 
sample 16.43 10288 20.81 4262 24.38 33867 
              
AVG 16.21 8667 20.66 3488 24.32 34955 
STDEV 0.36 1562 0.22 790 0.13 7279 
% RSD 2.23 18.02 1.08 22.66 0.54 20.82 
 
 
Efficacy of incubations in the dual digestion method 
Incubation efficacy tests were conducted with the Darbe and the rhEPO standard 
samples in order to determine the ideal time of the first incubation to denature the protein 
samples and the ideal time of the second incubation to deactivate trypsin in the protein 
samples. The Darbe and rhEPO standard samples were analyzed by the Guan et al. 2008 
substituted with the (ISU) developed HPLC gradient method. The results were plotted as 
concentrations recovered versus incubation times.  The conversion of concentrations from the 
integrated peak mass areas for each incubation experiment was calculated by taking the 
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sample with the highest integrated peak mass area (the average of T17, T6, and T9 areas) as 
the standard by assuming that the standard had 100% protein recovery. This standard was 
used to calculate the concentration by one point calibration for the purpose of this 
experiment. So, concentrations could be used to compare protein recovery for each 
incubation time points instead of comparing individual integrated peak mass areas. 
For the first incubation efficacy experiment of rhEPO, 400 ppb of rhEPO standard 
was prepared from the  rhEPO stock solution. The 400 ppb rhEPO standard solution was 
aliquot in equal volumes into three different 1.5 mL plastic centrifuge tubes. The first 
incubations of the samples were at 5, 7, and 10 minutes at 80 oC for denaturation. Then, all 
samples were incubated a second time for 3 minutes at 80 oC for trypsin deactivation. The 
dual digest samples were analyzed by LC-MS. The 7 and 10 minutes samples after the first 
incubation efficacy experiment of rhEPO had similar results (Figure 13). The 5 minute 
rhEPO sample incubation had the lowest recovery of the proteins (Figure 13).
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Figure 13. First Incubation Efficacy of rhEPO: Denaturation of rhEPO standard samples. Each bar represents 
the average of T17, T6, and T5 peptides concentrations versus incubation time. The 400 ppb rhEPO standard 
samples were analyzed by the Guan et al. 2008 substituted with the (ISU) developed HPLC gradient method. 
LC-MS was in ESI+ and selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4), and 
T5 (m/z 897.8) peptide ions in MS/MS. The concentration in parts per billion (ppb) was determined based on 
one point calibration using sample with the largest peak area as the standard by assuming that the standard had 
100% recovery of the proteins. One microgram of rhEPO is equal to 200 units. 
 
 For the second incubation efficacy of rhEPO, equal volumes of 400 ppb rhEPO 
standard samples were aliquoted into five 1.5-mL microcentrifuge tubes and incubated for 10 
minutes at 80 oC for denaturation. For the second incubation, the samples were divided into 
different incubation time points and incubated at 1, 2, 3, 5, and 10 minutes at 80 oC for 
trypsin deactivation. The 2, 3, and 5 minutes incubation times had the highest recovery of  
 57 
rhEPO (Figure 14). The one and 10 minute incubation times had the lowest recovery of 
rhEPO (Figure 14). 
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Figure 14. Second Incubation Efficacy of rhEPO: Trypsin deactivation of rhEPO standard samples. Each bar 
represents the average of T17, T6, and T5 peptides concentrations versus incubation time. The 400 ppb rhEPO 
standard samples were analyzed by the Guan et al. 2008 substituted with the (ISU) developed HPLC gradient 
method. LC-MS was in ESI+ and selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 
766.4), and T5 (m/z 897.8) peptide ions in MS/MS. The concentration in parts per billion (ppb) was determined 
based on one point calibration using sample with the largest peak area as the standard by averaging that the 
standard had 100% recovery of the proteins. One microgram of rhEPO is equal to 200 units. 
 
In the first incubation efficacy test of Darbe, 50 ppb of Darbe standard solution was 
prepared from rhEPO stock solution. The 50 ppb Darbe standard solution was aliquoted in 
equal volume into three different 1.5 mL plastic centrifuge tubes. In the first incubation, the 
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samples were divided into different incubation time points and incubated at 5, 7, and 10 
minutes at 80 oC for denaturation. Then, all samples were incubated for 3 minutes at 80 oC 
for trypsin deactivation. The 5 and 7 minutes had similar amount of recovery of Darbe 
(Figure 15). The 10 minutes incubation time had the lowest recovery of Darbe (Figure 15). 
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Figure 15. First Incubation Efficacy of Darbe: Denaturation of Darbe standard samples. Each bar represents the 
average of T17, T6, and T5 peptides concentrations versus incubation time. The 50 ppb Darbe standard samples 
were analyzed by the Guan et al. 2008 substituted with the (ISU) developed HPLC gradient method. ESI+ and 
selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4), and T5 (m/z 897.8) peptide 
ions in MS/MS was used. The concentration in parts per billion (ppb) was determined based on one point 
calibration using sample with the largest peak area as the standard by assuming that the standard had 100% 
recovery of the proteins. One microgram of Darbe is equal to 800 units. 
 
In the second incubation efficacy experiment, equal volumes of 50 ppb Darbe 
standard were aliquoted into five 1.5-mL microcentrifuge tubes and incubated for 10 minutes 
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at 80 oC for denaturation. For the second incubation, the samples were divided into different 
incubation time points and incubated at 1, 2, 3, 5, and 10 minutes at 80 oC for trypsin 
deactivation. The 50 minutes incubation time had the highest recovery of Darbe (Figure 16). 
The 2, 3, 7, and 10 minutes had similar amount of protein recovery (Figure 16). The one 
minute incubation time had the lowest amount of protein recovery (Figure 16). 
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Figure 16. Second Incubation Efficacy of Darbe: Trypsin deactivation of Darbe standard samples. Each bar 
represents the average of T17, T6, and T5 peptides concentrations versus incubation time. The 50 ppb Darbe 
standard samples were analyzed by the Guan et al. 2008 substituted with the (ISU) developed HPLC gradient 
method. ESI+ and selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4), and T5 
(m/z 897.8) peptide ions in MS/MS was used. The concentration in parts per billion (ppb) was determined based 
on one point calibration using sample with the largest peak area as the standard by assuming that the standard 
had 100% recovery of the proteins. One microgram of Darbe is equal to 800 units.
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Efficacy of trypsin in the dual digestion method 
Four 2.5 ppb Darbe-spiked plasma samples were analyzed by the Guan et al. 2007 
method (Table 13) for investigation of trypsin digestion efficacy. The amount of trypsin and 
incubation time to denature protein samples recommended by the Guan et al. 2007 method 
were 2 µg (23.3 µg trypsin per mL of sample digest) and 10 minutes, respectively. The Darbe 
spiked samples were analyzed in four different conditions: no incubation with 2 µg (23.3 µg 
trypsin per mL of sample digest), 10 minutes incubation with 2 µg (23.3 µg trypsin per mL of 
sample digest) and 4 µg (46.6 µg trypsin per mL of sample digest) of trypsins, and 20 
minutes incubation with 2 µg trypsin (23.3 µg trypsin per mL of sample digest) (Table 13). 
The doubling in trypsin concentration slightly improved the recovery of both tryptic peptide 
fragments (T17 and T6) even without protein denaturation (Table 13). The 2 µg (23.3 µg 
trypsin per mL of sample digest) and the 4 µg (46.6 µg trypsin per mL of sample digest) of 
trypsins use for the two 10 min incubation samples had similar results in the integrated peak 
mass areas by LC-MS (Table 13). The sample with the 20 minute protein denaturation time 
and 2 µg (23.3 µg trypsin per mL of sample digest) of trypsin had the lowest integrated peak 
mass area (Table 13). 
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Table 13. Efficacy of trypsin. Four 2.5 ppb Darbe-spiked plasma samples were analyzed by the Guan et al., 
2007 method. Zero incubation time means no denaturation of samples. The samples were analyzed by LC-MS 
ESI+ in selected ion monitoring (SIM) of T17 (m/z 450) and T6 (m/z 464.5) peptide ions in MS/MS. PA is the 
integrated peak mass area of EIC for T17 and T6 peptides. The PA was the average of two LC-MS injections. 
Two µg trypsin = 23.3 µg trypsin per mL of sample digest and 4 µg trypsin = 46.6 µg trypsin per mL of sample 
digest. 
Sample Description 
 Incubation 
Time (min) 
Trypsin 
Amount T17 (PA) T6 (PA) 
2.5 ppb Darbe-spiked plasma 0 4 µg 7049 2749 
2.5 ppb Darbe-spiked plasma 10 2 µg 6672 2628 
2.5 ppb Darbe-spiked plasma 10 4 µg 6255 2629 
2.5 ppb Darbe-spiked plasma 20 2 µg 5750 2468 
 
The efficacy of trypsin in the dual digestion with trypsin and PNGase F was 
investigated (Table 14). The 50 ppb Darbe standard solution was prepared from standard 
stock solution. Equal volumes of 50 ppb Darbe standard were aliquot into two 1.5 mL plastic 
centrifuge tubes. For the dual digestion, the two tubes where placed in 80 oC for 10 minutes. 
After denaturation, 2 µg (24.7 µg trypsin per mL of sample digest) and 4 µg (49.4 µg trypsin 
per mL of sample digest) of trypsins were added into each tube. After trypsin digestion, the 
tubes were incubated the second time for 7 minutes at 80 oC to deactivate trypsin. The 
samples were analyzed by the Guan et al. 2008 substituted with the (ISU) developed HPLC 
gradient  method. The recovery of T17 tryptic peptide fragments doubled as the concentration 
increased from 2 µg (24.7 µg trypsin per mL of sample digest) to 4 µg (49.4 µg trypsin per 
mL of sample digest) of trypsins (Table 14). Also, the recovery of T6 and T9 peptide 
fragments increased as the trypsin concentration was doubled (Table 14). 
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Table 14. Efficacy of trypsin. Fifty ppb Darbe standard samples were analyzed by the Guan et al. 2008 
substituted with the (ISU) developed HPLC gradient  method. The first and second incubations were 10 and 7 
minutes, respectively, in dual digestion procedure. The samples were analyzed by LC-MS ESI+ in selected ion 
monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4) & T5 (m/z 897.8) peptide ions in MS/MS. 
PA is the integrated peak mass area of EIC for T17 and T6 peptides. The PA was the average of two LC-MS 
injections. Two µg trypsin = 24.7 µg trypsin per mL of sample digest and 4 µg trypsin = 49.4 µg trypsin per mL 
of sample digest. 
Sample Description 
Trypsin 
Amount T17 (PA) T6 (PA) T9 (PA) 
50ppb Darbe standard dual digest 2 µg 1177 821 7385 
50ppb Darbe standard dual digest 4 µg 2653 857 7518 
 
 
Effectiveness of PNGase F enzymes in Darbe digestion 
An experiment was designed to test the efficacy of peptide N-glycosidase F (PNGase 
F) enzyme in digestion of Darbe standard samples (Table 15). A 50 ppb Darbe standard 
sample was digested by the Guan et al. 2007 method, which had trypsin digestion only. 
Another 50 ppb Darbe standard sample was prepared by the Guan et al. 2008 dual digestion 
method, which had trypsin and PNGase F digestions. Twenty mL of acetonitrile was added to 
the Guan et al. 2007 Darbe standard digest to a final volume of 120 µL, so that it would be 
equal to the final volume of the Guan et al. 2008 dual digest method of 120 µl. The two 
sample digests were analyzed by LC-MS with ISU LC gradient (Table 15). The T9 peptide 
ion was not detected for Darbe standard treated with trypsin only (Table 15). The T9 peptide 
ion was detected for Darbe standard treated with trypsin and PNGase F enzymes with a 
integrated peak mass area (PA) of almost seven thousands (Table 15). The T7 peptide 
integrated peak mass area for Darbe standard treated with trypsin and PNGase enzymes was 
almost two times greater than the integrated peak mass area for Darbe standard treated with 
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trypsin only (Table 15). The integrated peak mass area for T6 peptide increased from 811 
(trypsin digest) to 961 for Darbe samples treated with trypsin and PNGase F. 
 
Table 15. Efficacy of PNGase F after trypsin digestion. 50 ppb Darbe standard samples with and without 
PNGase F enzymes were prepared by the Guan et al., 2008 and the Guan et al., 2007 digestion methods, 
respectively. The sample digests were analyzed by LC-MS ESI+ in selected ion monitoring (SIM) of T17 (m/z 
450), T6 (m/z 464.5), T9 (m/z 766.4) & T5 (m/z 897.8) peptide ions in MS/MS. PA is the integrated peak mass 
area of EIC for T17, T6, & T5 peptides. The PA was the average of two LC-MS injections. 
Sample Name PNGase F T17 (PA) T6 (PA) T9 (PA) 
a50 ppb Darbe standard Trypsin digest No 581 811 ND 
b50 ppb Darbe standard dual digest Yes 1004 961 6820 
aThe sample digest was prepared by the Guan et al. 2007 digestion method plus 20 µL acetonitrile. 
bThe sample digest was prepared by the Guan et al. 2008 dual digestion method. 
 
 
Dual digestion method evaluation 
The dual enzyme digestion of the Guan et al. 2008 method was 10 minutes each for 
the first and second incubations to denature the samples and to deactivate trypsin, 
respectively. Furthermore, the Guan et al. 2007 and 2008 methods used 2 µg of trypsin (24.7 
µg trypsin per mL of sample digest). Based on the incubation efficacy results in this report, 7 
minutes for the first incubation (sample denaturation) and 5 minutes for the second 
incubation (trypsin deactivation) with doubling the trypsin concentration (from 2 µg to 4 µg 
per sample) gave the optimal dual digestion condition from the conditions tested for Darbe 
and possibly rhEPO samples. In this experiment, the dual enzyme digestion condition of the 
Guan et al. 2008 method was compared with the modified trypsin concentration and modified 
incubations conditions (Table 16). A 50 ppb Darbe standard solution was made from stock 
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standard solution.  Equal volume of 50 ppb standard solution was aliquoted into 1.5 mL 
plastic centrifuge tubes and analyzed according to the experimental conditions of Table 16.  
The integrated peak mass areas and concentrations increased from left to right for the 
modified conditions: 10 min and 5 min with 2 µg trypsin, 7 min and 5 min with 2 µg trypsin, 
and 7 min and 5 min with 4 µg trypsin (Table 16). The 10 min and 10 min with 2 µg trypsin 
had the lowest overall protein recovery (Table 16). The 7 minutes and 5 minutes with 4 µg of 
trypsin had the highest recovery for all three peptides (Table 16). The calculated 
concentration for 7 minutes and 5 minutes incubations with 4 µg trypsin (49.4 µg trypsin per 
mL of sample digest)  increased from 33.8 ppb (10 minutes and 10 minutes incubations with 
2 µg) to 50 ppb (Table 16).  
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bConcentration 
(ppb) 
33.0 
33.8 
36.4 
50.0 
aSum  of 
PA 
4981 
5009 
5515 
7585 
T9 
(PA) 
3663 
3859 
4319 
5738 
T6 
(PA) 
402 
346 
362 
531 
RESULTS 
T17 
(PA) 
826 
805 
833 
1315 
Trypsin 
Amount 
2 µg 
2 µg 
2 µg 
4 µg 
Second 
Incubation 
(min.) 
10 
5 
5 
5 
Experimental Conditions 
First 
Incubation 
(min.) 
10 
10 
7 
7 
Sample Description 
50 ppb Darbe standard dual 
digest 
50 ppb Darbe standard dual 
digest 
50 ppb Darbe standard dual 
digest 
50 ppb Darbe standard dual 
digest 
aThe sum of T17, T6, & T9 integrated peak mass area. 
bThe calculation of concentration in ppb (ng/mL, 0.8 units = 1 ng) was based on one point calibration using sample with the largest peak area 
from the sum of areas as the standard by assuming that the standard had 100% recovery of proteins for the purpose of this experiment. 
 
Table 16. Efficacy of Darbe sample incubations and trypsin digestion. The incubations and trypsin concentration conditions of Guan et al. 2008 
method was compared with the modified incubations and trypsin concentration conditions. The Darbe dual digest samples were analyzed by 
LC-MS with ISU gradient. Each sample was made in triplicates and injected twice per sample into the LC-MS. The reported results were 
averaged of six LC-MS injections. LC-MS analysis was in ESI+ and selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 
766.4) & T5 (m/z 897.8) peptide ions in MS/MS. PA is the integrated peak mass area of EIC. Two µg trypsin = 23.3 µg trypsin per mL of 
sample digest and 4 µg trypsin = 46.6 µg trypsin per mL of sample digest. 
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Standard curves of Darbe and rhEPO spiked plasma 
The 7 minutes and 5 minutes incubations with 4 µg  trypsin (49.4 µg trypsin per mL 
of sample digest) was determined to be the optimal condition for the dual digestion method 
(Table 16). The Guan et al. 2008 method substituted with the (ISU) HPLC gradient and with 
7 minutes first incubation, 5 minutes second incubation, and 4 µg (49.4 µg trypsin per mL of 
sample digest) trypsin dual digestion conditions will be abbreviated as “the resulting (ISU) 
method or the resulting (ISU) method modified from the Guan et al. 2007 and 2008 methods” 
from now on.   
Darbe spiked plasma samples at 0.05, 0.1, 0.2, 0.5, and 2.5 ppb were analyzed by the 
resulting (ISU) method and a standard curve was generated (Figure 17). The lowest 
concentration was determined to be 0.05 ppb in all three peptides for Darbe spiked plasma 
samples with a signal-to-noise ratio of 3 and greater for T17 and T6 and one for T9 peptides 
(Figure 17). The R-square values determined by linear regression for T17, T6, and T9 
peptides were 0.9989, 0.9969, and 0.9913, respectively (Figure 17). 
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Figure 17.  Darbe spiked plasma range from 0.05 to 2.5 ppb samples were analyzed by the resulting (ISU) 
method modified from the Guan et al. 2007 and 2008 methods. LC-MS analysis was in ESI+ and selected ion 
monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4) & T5 (m/z 897.8) peptide ions in MS/MS. 
PA is the integrated peak mass area of EIC. Each sample was injected twice into the LC-MS. AVG is the 
average of T17, T6, and T9 integrated peak mass areas. 
 
The rhEPO spiked plasma samples at 0.1, 0.2, 0.5, 1.0, 2.5, 5, and 20 ppb were 
prepared and analyzed according to the resulting (ISU) method modified from the Guan et al. 
2007 and 2008 methods. The lowest concentrations for rhEPO spiked plasma were 
determined to be 0.1, 0.5, and 0.1 ppb for T17, T5, and T6 peptides, respectively (Figure 18). 
Also, the signal-to-noise ratio for T17, T6, and T5 were 4, 4, and one, respectively. The R-
square values were determined to be 0.9919, 0.9955, and 0.9794 for T17, T6, T5 peptides, 
respectively (Figure 18). 
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Figure 18.  The rhEPO spiked plasma range from 0.05 to 2.5 ppb samples were analyzed by the resulting (ISU) 
method modified from the Guan et al. 2007 and 2008 methods. LC-MS analysis was in ESI+ and selected ion 
monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4) & T5 (m/z 897.8) peptide ions in MS/MS. 
PA is the integrated peak (mass) area of EIC. Each sample was injected twice into the LC-MS. AVG is the 
average of T17, T6, and T9 integrated peak mass areas. 
 
 
Detection of Darbe administration plasma samples 
A 20-year old female horse that weighed 527 kg was dosed by intramuscular (IM) 
injection at 0.4 µg/kg of Darbe. Blood samples were collected before and after IM injection 
for up to 192 hours. After dosing the horse with Darbe, the blood was collected from the 
horse at 2, 4, 6, 8, 24, 48, 72, 96, 168, and 192 hours (Figure 19). The Darbe administration 
(admin) plasma samples were analyzed by the resulting (ISU) method modified from the 
Guan et al. 2007 and 2008 methods. The T6, T17, and T9 peptide ions were not detected for 
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plasma sample collected before the horse was dosed with Darbe (Figure 19). The T6, T17, 
and T9 peptide ions were detected from Darbe admin samples from 2 to 192 hours (Figure 
19).  
The Darbe plasma concentrations calculated by T6, T17, and T9 peptides were not 
consistent between different time points (Figure 19). For example, the concentration for the 8 
hours sample versus to the 24 hours sample were 12.3 ppb versus 13.3 ppb, respectively, for 
T6; 11.5 ppb versus 10.5 ppb, respectively for T17; and approximately the same for T9 
peptides (Figure 19). Therefore, the integrated peak mass areas of T6, T9, and T5 peptides for 
the Darbe admin samples were averaged for each time points. The averaged integrated peak 
mass areas of the peptides of the samples were plotted into a standard curve generated with 
the averaged of T6, T9, and T5 integrated peak mass area versus the spiked plasma 
concentrations (Figure 17) to calculate the concentrations of Darbe in plasma samples (Figure 
20). This increased the consistency of protein concentrations calculated for Darbe admin 
samples (Figure 20). The Darbe drug was not detected in the pre-injection (time zero) sample 
(Figure 20). The Darbe concentration in admin plasma increased from time of injection to 4 
hours (Figure 20). The 2 and 4 hours post-injection plasma samples had 15.2 ppb and 16.1 
ppb of the Darbe compounds, respectively (Figure 20). At six hours, the drug began to be 
eliminated in horse plasma from 14.6 ppb down to 1.5 ppb at 192 hours (Figure 20). 
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Figure 19. Elimination of Darbe in equine plasma versus time from 0 to 192 hours. The samples were analyzed 
by the resulting (ISU) method modified from the Guan et al. 2007 and 2008 methods. LC-MS analysis was in 
ESI+ and selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4) & T5 (m/z 897.8) 
peptide ions in MS/MS. PA is the integrated peak mass area of EIC. The PA of  T17, T6, and T9 peptides were 
plotted into the standard linear equations of T17, T6, & T9, respectively, of Figure17 to calculate the plasma 
concentrations of Darbe. The time (hours) is the time of blood sample collections from the horse. The table at 
bottom of graph listed the concentration in ppb for each of the peptides versus time (hours), which is listed on 
the x-axis. Each sample was injected twice into the LC-MS. The two data were averaged. Zero is the blood 
sample collected at pre-injection time. Parts per billion = ppb. 
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Figure 20. Elimination of Darbe in equine plasma versus time from 0 to 192 hours. The samples were analyzed 
by the resulting (ISU) method modified from the Guan et al. 2007 and 2008 methods. LC-MS analysis was in 
ESI+ and selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4) & T5 (m/z 897.8) 
peptide ions in MS/MS. PA is the integrated peak mass area of EIC. The average of T17, T6, and T9 peptides 
PA were plotted into the standard linear equations from the average of T17, T6, & T9 of Figure 17 to calculate 
the plasma concentrations of Darbe. The time (hours) is the time of blood sample collections from the horse. 
Each sample was injected twice into the LC-MS. The two data were averaged. Zero is the blood sample 
collected at pre-injection time. Parts per billion = ppb. 
 
Figures 21 and 22 showed examples of EIC of the horse before dosed (Figure 21) and 
after twenty four hours of Darbe injection into the 20 years old female horse (Figure 22). The 
first and second rows of chromatograms of Figures 21 and 22 were T17 and T6 peptides, 
respectively, for confirmation of Darbe or rhEPO. The third row of chromatograms of Figures 
21 and 22 were for differentiation of Darbe by T9 peptide. The last row of chromatograms of 
Figures 21 and 22 were for differentiation of rhEPO by T5 peptide fragment. Blood samples 
collected before Darbe injection showed no detection of any of the tryptic peptide fragments 
(Figure 22). On the other hand, the 24 hours plasma sample from the horse administered with 
Darbe were detected for the T17, T6, and T9 peptides (Figure 21). The T5 peptides use for 
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differentiation of rhEPO from other compounds in the plasma samples were not detected 
(Figure 21 & 22). 
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Figure 21. EIC of Darbe dosed in horse after 24 hours. Blood samples were collected 24 hours after IM injection of Darbe into the horse. The 
collected plasma sample was analyzed by  the resulting (ISU) method modified from the Guan et al. 2007 and 2008 methods. LC-MS analysis was in 
ESI+ and selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4), & T5 (m/z 897.8) peptide ions in MS/MS. The left side 
of the chromatogram showed the retention time and peak mass areas of the peptides. The right side of the chromatogram showed the selected product 
ions of the peptides. RT = retention time. MA = integrated peak mass area. SN = signal to noise ratio. 
C:\Xcalibur\Data\041308\LTX041308A56 4/16/2008 12:01:47 AM 24 Hr DPO Admin plasma 04/09/08 #13
ZBX300SB-C18:1x50mm;0to33in35@50 ul/min
14.0 14.5 15.0 15.5 16.0 16.5 17.0 17.5
Time (min)
0
50
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
RT: 16.44
MA: 11357
SN: 637
16.30 16.6115.25 17.0714.23 15.73 17.3114.39 14.89
NL: 1.04E3
m/z= 
234.50-235.50+262.50-263.50+
635.50-636.50 F: ITM S + c ESI w Full 
ms2 450.00@cid25.00 [200.00-850.00]  
M S LTX041308A56
200 250 300 350 400 450 500 550 600 650 700 750 800 850
m/z
0
20
40
60
80
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
636.41
263.16
618.44 781.48391.33 549.43309.80 646.45418.47 745.53522.59 810.49
19.0 19.5 20.0 20.5 21.0 21.5 22.0
Time (min)
0
50
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
RT: 21.04
MA: 4800
SN: 323
21.4119.60 20.7619.86 20.51 21.7420.1219.27
NL: 4.98E2
m/z= 213.50-214.50+713.50-714.50 F: 
ITM S + c ESI w Full ms2 
464.50@cid25.00 [200.00-850.00]  
M S LTX041308A56
200 250 300 350 400 450 500 550 600 650 700 750 800 850
m/z
0
20
40
60
80
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
714.39
404.32 567.34
828.45479.26214.12 333.28 507.21361.28 811.44764.35578.32419.98 665.25298.22234.13
22 23 24 25 26
Time (min)
0
50
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
RT: 24.32
MA: 44878
SN: 104
25.9424.58 24.9523.8522.19 22.89 23.25
NL: 4.72E3
m/z= 
799.60-800.60+857.10-858.10+906.60-907.60+
963.10-964.10+1019.60-1020.60+1055.30-1056.30 F: ITM S 
+ c ESI Full ms2 766.40@cid25.00 [700.00-1100.00]  M S 
LTX041308A56
700 750 800 850 900 950 1000 1050 1100
m/z
0
20
40
60
80
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
907.26
963.81
857.67 1055.85
1020.32
800.18701.93 898.14 954.72848.69739.44 1011.37 1046.86 1082.63784.41
18 19 20 21 22
Time (min)
0
20
40
60
80
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
21.26 21.47
20.70
21.5620.91
19.27 19.85
19.9518.5618.35 19.16 20.3819.65
17.99
NL: 2.05E1
m/z= 
459.80-460.80+659.80-660.80+776.90-777.90+965.10-966.10+
1015.40-1016.40+1066.20-1067.20+1115.10-1116.10 F: ITM S + c ESI 
Full ms2 897.80@cid25.00 [400.00-1200.00]  M S 
LTX041308A56
400 500 600 700 800 900 1000 1100 1200
m/z
0
20
40
60
80
100
R
e
l
a
t
i
v
e
 
A
b
u
n
d
a
n
c
e
797.42
840.13788.76
638.44 853.76507.31 1141.861051.82988.30620.54 725.47467.34 950.59
T17 peptide ion 
T17 product ions by 
MS/MS identified 
T6 product ions by 
MS/MS identified 
T9 product ions by 
MS/MS identified 
T5 product ions by 
MS/MS not detected 
T6 peptide ion 
T9 peptide ion 
T5 peptide ion 
not detected 
 
74
 
Figure 22. EIC of horse plasma before dosed with Darbe. Blood samples were collected before IM injection. The collected plasma sample was 
analyzed by the resulting (ISU) method modified from the Guan et al. 2007 and 2008 methods. LC-MS analysis was in ESI+ and selected ion 
monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4), & T5 (m/z 897.8) peptide ions in MS/MS. The left side of the chromatogram 
showed the retention time and peak mass areas of the peptides. The right side of the chromatogram showed the selected product ions of the peptides. 
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Detection of rhEPO administration plasma samples 
 A 12-year old horse that weighs 524 kg was dosed by intravenous (IV) injection at 0.3 
µg/kg of epoetin alfa (rhEPO). Blood samples were collected before and after 4 hours of IV 
injection. The collected plasma samples were analyzed by the resulting (ISU) method 
modified from the Guan et al. 2007 and 2008 methods.   
The rhEPO injected by IV injection into horse was detected after four hours for T17, 
T6, and T5 peptide ions (Table 17).  None of the peptides were detected for the zero hour 
(pre-injection) sample (Table 17). The concentrations for 4 hours admin samples were 10 
ppb, 10 ppb, and 1.2 ppb for T17, T6, and T5 peptides, respectively, (Table 17). It would be 
more consistent to calculate rhEPO concentration by averaging the three peptides similar to 
the way that it was done for Darbe admin samples. However, a reliable rhEPO standard curve 
cannot be produced because a valid rhEPO standard was not available. The rhEPO data 
generated was to show that the method could be used to detect rhEPO admin plasma samples 
and would not be used for comparison with Darbe data. 
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Table 17. Elimination of rhEPO in equine plasma versus time from 0 to 4 hours. The samples were analyzed by 
the resulting (ISU) method modified from the Guan et al. 2007 and 2008 methods. LC-MS analysis was in ESI+ 
and selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 464.5), T9 (m/z 766.4), & T5 (m/z 897.8) peptide 
ions in MS/MS. PA is the integrated peak mass area of EIC. The PA of T17, T6, and T9 peptides were plotted 
into the standard linear equations of T17, T6, & T9, respectively, of Figure18 to calculate the plasma 
concentrations of rhEPO. The rhEPO samples were prepared in duplicates and injected twice into the LC-MS. 
The data were averaged. The time (hours) is the time of blood sample collections from the horse. Zero means 
pre-injection. 
Sample Description 
T17 peptide 
(ppb) 
T6 peptide 
(ppb) 
T9 peptide 
(ppb) 
T5 peptide 
(ppb) 
rhEPO admin plasma, 0 hour ND ND ND ND 
rhEPO admin plasma, 4 hours 10.0 10.0 ND 1.2 
 
 
Percent recovery of Darbe in Darbe spiked plasma samples 
 A 50 ppb Darbe standard was prepared and analyzed the same time with the Darbe 
spiked-plasma samples of Figure 17 by the resulting (ISU) method modified from the Guan et 
al. 2007 and 2008 methods. The results of the 50 ppb Darbe standard digest was used to 
calculate the amount of Darbe recover in the Darbe spiked-plasma digests of Figure 17. The 
amount of Darbe recovery by the extraction process can be determined by using the 50 ppb 
Darbe standard digest as a standard to calculate the amount of Darbe recovered in the Darbe 
spiked samples.   
The 50 ppb Darbe standard was injected twice into the LC-MS. The integrated peak 
mass areas of the two injections were averaged. The averaging method (the average of T17, 
T6, and T9 integrated peak mass areas for standard and samples) was used to calculate the 
percent of Darbe recovered in Darbe spiked plasma samples of Figure 17 by one point 
calibration (Table 18). The percent of Darbe recovered for the 0.05 to 0.5 ppb Darbe-spiked 
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plasma samples were 100% although the calculated percent recovery for those samples were 
greater than 100% (Table 18). The cause of higher than 100 % recovery was probably due to 
the discrepancy of the peptide fragments generated and injection error (Table 18). The 
percent deviation increased from 109% to 152% for the 0.2 ppb and 0.05 ppb samples, 
respectively, as the concentrations of the Darbe-spiked plasma samples decreased from 0.2 
ppb to 0.05 ppb (Table 18). The decrease in concentration was associated with the decrease in 
peak height indicating that the error was partially caused by low signal-to-noise ratio (Table 
18). The percent recovery of Darbe for the 2.5 ppb Darbe-spiked plasma sample was 83.4% 
(Table 18). 
 
Table 18. Percent recovery by affinity purification of Darbe in the 0.05 to 2.5 ppb Darbe-spiked plasma 
samples. The samples were analyzed by the resulting (ISU) method modified from the Guan et al. 2007 and 
2008 methods. LC-MS analysis was in ESI+ and selected ion monitoring (SIM) of T17 (m/z 450), T6 (m/z 
464.5), T9 (m/z 766.4), & T5 (m/z 897.8) peptide ions in MS/MS. The samples were injected twice into the LC-
MS. The data reported was averaged of two injections. Nanograms = ng. 
Sample Description 
Amount Darbe 
Spiked in Plasma 
(ng) 
Amount Darbe 
Recover 
(ng) 
Recovery 
(%) 
0.05 ppb Darbe standard spiked plasma 0.83 1.27 152 
0.1 ppb Darbe standard spiked plasma 1.67 2.09 125 
0.2 ppb Darbe standard spiked plasma 3.33 3.87 116 
0.5 ppb Darbe standard spiked plasma 8.33 9.08 109 
2.5 ppb Darbe standard spiked plasma 41.67 34.76 83.4 
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CHAPTER 5. CONCLUSION 
 
 The Guan et al. 2007 method has been replicated by using trypsin cleavage fragments 
6 (T6) and 17 (T17) that are unique only to Darbe and rhEPO. The Guan et al. 2008 method 
had also been replicated that could differentiate Darbe from rhEPO and vice versa. The 
differentiation method utilized the T9 fragment of Darbe that is unique only to this 
glycoprotein (Guan et al., 2008). In addition, the fifth tryptic peptide fragment of rhEPO was 
used to differentiate rhEPO from other proteins.  
The results indicated that BSA interfered with trypsin digestion activities resulting in 
low detection of Darbe and rhEPO in samples. The rhEPO stock solution use was in a sterile 
buffer with BSA. Therefore, rhEPO standard was not used as a valid standard in this study. A 
LC mobile phase gradient method was developed to analyze the four peptide fragments (T17, 
T6, T9, and T5). The separated peptide fragments can be used to confirm Darbe or rhEPO in 
one analysis. Therefore, results were produced using less sample in less time. 
An average of twenty percent variability in integrated peak area for each T17, T6, and 
T9 peptides was determined in reproducing the Guan et al. 2008 method. The averaging 
calculation method was applied to increase the consistency of the results generated. The ideal 
condition for analysis of Darbe and rhEPO in plasma sample was determined to be 7 min for 
first incubation and 5 min for second incubation at 80 oC with 4 micrograms of trypsin. 
The LC-MS ESI+ detection of T17 and T6 peptide ions improved after rhEPO and 
Darbe were treated with PNGase F enzymes. The glycans attachment on T9 and T5 tryptic 
peptide fragments suppressed ionization in positive ion mode (Guan et al., 2008). The T9 
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peptide ion from Darbe sample not treated with PNGase F enzyme was not detected by LC-
MS (Table 15) because T9 and T5 were the glycosylation sites of Darbe (Egrie et al., 2003; 
Nimtz et al., 1993), Therefore, the detection of T9 was suppressed by the glycan attachment. 
The T5 peptide ion of rhEPO would not be detected if rhEPO was not treated with PNGase F. 
On the contrary, the T9 tryptic peptide fragment from Darbe samples treated with PNGase F 
was detected (Table 15). Although T17 and T6 were not the glycosylation sites of Darbe 
(Egrie et al., 2003; Nimtz et al., 1993), Darbe sample treated with PNGase F had higher 
integrated peak mass areas for T17 and T6 than the untreated Darbe sample (Table 15). 
Therefore, it is possible that T17 and T6 may have a small unit of glycans attachment that 
may interfere with ionization of T17 and T6 fragments in ESI+ mass spectrometric detection 
(Guan et al., 2008). 
Darbe injected by intramuscular (IM) injection into the horse was detected in admin 
plasma samples for up to 192 hours. An averaging method was used to calculate the 
concentrations of Darbe in admin samples in order to increase the consistency of results. The 
discrepancy between the tryptic peptide fragments may be partially due to enzyme digestion 
issues. There is a possibility that this issue can be improved by increasing the trypsin and 
PNGase enzymes concentrations. Finally, rhEPO dosed by intravenous (IV) injection into 
another horse was detected in admin plasma samples. No protein drugs were detected in 
plasma from untreated horses. 
The results of Figure 20 were used to determine the half-life of Darbe in the horse 
administered by IM injection. The half-life was qualitatively estimated to be 44 hours by 
using the 44 hours (16.1 ppb) and the 48 hours (8.2 ppb) data points of Figure 20 (48 hours 
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minus 4 hours equals to 44 hours since 8.2 ppb is approximately half of 16.1 ppb). The 
pharmacokinetics data showed that the half-life of Darbe administered by subcutaneous 
injection into human was an average of 48.4 hours (MacDougall et al., 1999). This 
comparison shows that the half-life of Darbe administered in horse by IM injection is similar 
to the half-life of Darbe administered in human by subcutaneous injection. 
 In future study, plasma samples collected from dosing rhEPO into horse can be 
analyzed when a valid rhEPO standard becomes available. The LOD of rhEPO can also be 
determined in spiked equine plasma. Also, lower than 0.05 ppb Darbe-spiked plasma needs to 
be tested since the LC-MS sensitivity was improved with the ISU method.  Finally, a test can 
be conducted to determine whether increasing the concentration of trypsin and PNGase F can 
increase the consistency of reproducing results cause by the discrepancy of the peptide 
fragments. 
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